Document:

EX-4.1

 Exhibit 4.1 

SUBSCRIPTION AGREEMENT 

THIS SUBSCRIPTION AGREEMENT (this “Agreement”) is made and entered into as of December 19,
2015 (the “Effective Date “), by and between CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) organized under the laws of Switzerland and registered under the registration
number CHE-494.642.722 (the “Company”), Bayer Global Investments B.V., a Dutch private company with limited liability (Besloten vennootschap met beperkte aansprakelijkheid)
(“Subscriber”). 
 WHEREAS, the Company and Subscriber are
parties to that certain Joint Venture Agreement, dated as of even date herewith (as amended, restated, or otherwise modified from time to time, the “JV Agreement”); 

WHEREAS, the shareholders of the Company are parties to that certain Shareholders’ Agreement dated as
of 13 April 2015 (as amended, restated, or otherwise modified from time to time, the “Shareholders’Agreement”); and 

WHEREAS, in connection with entering into the JV Agreement, the Company and Subscriber desire to enter into
this Agreement, pursuant to which Subscriber agrees to subscribe for shares of the Company’s common shares with a nominal value of CHF 0.10 each (as may be adjusted prior to the IPO (the “Common Stock”) in a private
placement that would close concurrently with the IPO (as defined below) as described herein. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the foregoing recitals and the mutual promises, representations, warranties, and covenants
hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

 1. SUBSCRIPTION REQUIREMENT. In the event that the Company
consummates an initial public offering of its Common Stock pursuant to an effective registration statement under the Securities Act of 1933, as amended, or a foreign equivalent thereof (collectively, the “Securities Act”)
(the “IPO”), Subscriber shall subscribe for, subject to the terms and conditions set forth in this Agreement, in a concurrent private placement exempt from the registration requirements of the Securities Act, that number of
shares (the “Shares”) determined by dividing US$35,000,000 (thirty-five million US dollars) (the “Initial Subscription Amount”) by the price per share at which the Common Stock is sold to the public in
the IPO as set forth on the cover page of the prospectus, and such subscription will occur concurrently with, but conditioned upon, the closing of the IPO (the “Closing”). Notwithstanding anything herein to the contrary, if,
after Subscriber’s receipt of the Event Date Notice (as defined below) and on or before the Event Date (as defined below), the condition to closing set forth in Section 5.1(i) has not been satisfied or irrevocably and unconditionally
waived by Subscriber pursuant to Section 8.19(c), then the Initial Subscription Amount may be reduced in the sole and absolute discretion of the Company to any amount (including $0) as provided below (such amount, whether or not reduced, the
“Revised Subscription Amount”). In such case, the Company shall, at least fifteen (15) Business Days prior to the date that the Company anticipates filing the Registration Statement containing the “red
herring” prospectus that the Company expects to use in the roadshow for the IPO, provide written notice (the “Red Herring Notice”) to the Subscriber of such anticipated filing date and the Revised Subscription Amount. If
the condition to closing set forth in Section 5.1(i) has not been satisfied by the Company on or prior to the date of the Red Herring Notice, then the Subscriber shall have ten (10) Business Days from the date of such notice to either
(i) irrevocably and unconditionally waive the condition to closing set forth in Section 5.1(i) and accept the Revised Subscription Amount in such notice, or (ii) irrevocably and unconditionally waive its rights to subscribe for Shares
in the IPO pursuant to this Agreement. If the condition to closing set forth in Section 5.1(i) has been satisfied by the Company on or before the date of the Red Herring Notice, then the Subscriber shall be obligated to subscribe for Shares in
the IPO in an amount equal to the Revised Subscription Amount pursuant to this Agreement and the terms and conditions hereof (including the conditions to closing set forth in Section 5.1). The Revised Subscription Amount, or if there is no
Revised Subscription Amount, the Initial Subscription Amount, shall be referred to as the “Subscription Amount”. “Business Day” shall mean a day (other than a Saturday or Sunday) on which banks in
Basel, Switzerland, Leverkusen, Germany and Mijdrecht, the Netherlands are open for general business. 
 2. AGREEMENT TO
SELL AND SUBSCRIBE. 
 2.1 Closing. At the Closing, Subscriber agrees to subscribe for, and the Company agrees to issue to the
Subscriber, subject to the terms and conditions set forth in this Agreement, in a concurrent private placement exempt from the registration requirements of the Securities Act, the Shares at a price per share equal to the price at which the Common
Stock is sold to the public in the IPO as set forth on the cover page of the prospectus. 
 2.2 Closing Date. The Closing shall take
place at the date and time set for, and concurrently with, the closing of the IPO at the offices of VISCHER AG, Aeschenvorstadt 4, CH 4051 Basel, Switzerland, or such other time or place as the Company and Subscriber may mutually agree (the date of
such Closing is hereinafter referred to as the “Closing Date”). Promptly following the Closing, subject to the terms and conditions set forth in this Agreement 

  
 CRIPSR Therapeutics -
Participation Agreement 
 2 

 
and in consideration of the payment by Subscriber of the aggregate Subscription Amount for the Shares, the Company (or its transfer agent) will deliver after the registration of the Shares in the
register of commerce in Basel, Switzerland to Subscriber an extract from the duly signed share register evidencing the Subscriber as new owner of the Shares representing the Shares. 

2.3 Deliveries at Closing by Company. At the Closing, and upon satisfaction or waiver of the conditions set
forth in Section 5, the Company shall deliver to Subscriber (or an Affiliate of Subscriber as designated by Subscriber not later than five (5) Business Days before the Closing Date) (i) an subscription form in the form attached hereto
as Exhibit 1 (the “Subscription Form”) duly executed by the Company and (ii) the instruments, consents, certificates and other documents required of the Company pursuant to Section 5.1.

 2.4 Actions by Subscriber at Closing. Three (3) Business Days prior to Closing Subscriber shall have made or caused to
be made the payment of the nominal value of the Shares by wire transfer of immediately available funds to an escrow bank account in the sense of art. 633 para 1 Swiss Code of Obligations reasonably satisfactory to Subscriber designated in writing by
the Company to Subscriber not later than ten (10) Business Days before the Closing Date. Pursuant to Swiss law (art. 633 para 2 Swiss Code of Obligations) any amount in such escrow account will only be released to the Company after the Shares
have been registered in the commercial register of Basel, Switzerland. After the issuance of the Shares to the Subscriber (to take place following the satisfaction or waiver of the conditions set forth in Section 5), the Subscriber shall pay
the Subscription Amount minus the nominal value of the Shares already paid within five (5) Business Days starting from the day on which the Subscriber is provided with the duly signed share register evidencing the Subscriber as new owner of the
Shares. 
 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. 

On the date hereof, the Company hereby represents and warrants to Subscriber that the representations and warranties in Section 3.1, 3.2
and 3.3 are true and correct as of the date hereof. 
 3.1 Organization; Qualification. The Company is a corporation duly organized
and validly existing under the laws of Switzerland. The Company has all requisite corporate power and authority to own and operate its properties and assets, to execute and deliver this Agreement, to issue and sell the Shares, and to carry out the
provisions of this Agreement and to carry on its business as presently conducted. The Company is duly qualified to do business as a foreign corporation in all jurisdictions in which the nature of its activities and of its properties (both owned and
leased) makes such qualification necessary, except for those jurisdictions in which failure to do so would not have a material adverse effect on the Company or its business. 

3.2 Authorization; Binding Obligations. All corporate action on the part of the Company, its officers, directors and stockholders
necessary for the authorization of this Agreement, and the performance of all obligations of the Company hereunder has been taken. This Agreement, when executed and delivered, will be a valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights, and (b) as limited by
general principles of equity that restrict the availability of equitable remedies. 

  
 CRIPSR Therapeutics -
Participation Agreement 
 3 

 3.3 Non-Contravention. The execution, delivery and performance of this Agreement and the
consummation of the transactions contemplated hereby will not result in any violation or default (a) of any provision of its certificate of incorporation or articles of association, or (b) in any material respect of any provision of
(i) any instrument, judgment, order, writ or decree to which it is a party or by which it is bound, or (ii) any federal or state statute, rule or regulation applicable to the Company. No consent, approval, order or authorization of, or
registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority on the part of the Company is required in connection with the execution and delivery of this Agreement or the consummation of
the sale and issuance of Shares contemplated by this Agreement, except for the filing of notices of the sale of Shares pursuant to Regulation D promulgated under the Securities Act and applicable state securities laws. The Company is not in
violation or default (a) of any provision of its certificate of incorporation or articles of association, or (b) in any material respect of any provision of (i) any instrument, judgment, order, writ or decree to which it is a party or
by which it is bound, or (ii) any federal or state statute, rule or regulation applicable to the Company. 
 3.4
Closing Date Representations. On the Closing Date, the Company hereby represents and warrants to Subscriber that the following representations and warranties are true and correct as of the Closing (except to the extent any such representations
and warranties expressly relate to an earlier date, in which case such representations and warranties of the Company are true and correct as of such earlier date); provided, however, that the representations and warranties of the Company included
herein shall be deemed to be updated and modified by information included in the registration statement relating to the IPO (the “Registration Statement”), including but not limited to the final prospectus relating to
the IPO, a copy of which shall have been furnished to Subscriber as early as reasonably possible prior to the Closing and on which Subscriber shall be entitled to rely, including any prospectus filed pursuant to Rule 424 under the Securities Act,
and any free writing prospectuses, relating to the IPO. 
 (a) Organization; Qualification. The Company is a corporation
duly organized and validly existing under the laws of Switzerland. The Company has all requisite corporate power and authority to own and operate its properties and assets, to execute and deliver this Agreement, to issue and sell the Shares, and to
carry out the provisions of this Agreement and to carry on its business as presently conducted. The Company is duly qualified to do business as a foreign corporation in all jurisdictions in which the nature of its activities and of its properties
(both owned and leased) makes such qualification necessary, except for those jurisdictions in which failure to do so would not have a material adverse effect on the Company or its business. 

(b) Subsidiaries. The Registration Statement sets forth the subsidiaries of the Company, if any, immediately following the Closing. 

(c) Registration Statement. The Registration Statement and any prospectus contained therein do not, as of the filing date and effective
date of such Registration Statement, and as of the Closing Date, contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the
circumstances under which they were made, not misleading. 

  
 CRIPSR Therapeutics -
Participation Agreement 
 4 

 (d) Authorization; Binding Obligations. All corporate action on the part of the Company,
its officers, directors and stockholders necessary for the authorization of this Agreement, the performance of all obligations of the Company hereunder at the Closing and the authorization, sale, issuance and delivery of the Shares pursuant hereto
has been taken. This Agreement constitutes a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or
other laws of general application affecting enforcement of creditors’ rights, and (b) as limited by general principles of equity that restrict the availability of equitable remedies. 

(e) Valid Issuance of Shares. The Shares that are being subscribed for by Subscriber hereunder, when issued, sold and delivered in
accordance with the terms of this Agreement for the consideration expressed herein, will be duly and validly issued, fully paid, and nonassessable, and will be transferred to Subscriber free of liens, encumbrances and restrictions on transfer other
than (a) restrictions on transfer under this Agreement and under applicable state and federal securities laws, (b) restrictions on transfer under the lock-up agreement entered into by Subscriber for the benefit of the underwriters in the
IPO, and (c) any liens, encumbrances or restrictions on transfer that are created or imposed by Subscriber. Subject in part to the truth and accuracy of Subscriber’s representations set forth in Section 4 of this Agreement, the offer,
sale and issuance of the Shares as contemplated by this Agreement are exempt from the registration requirements of applicable state and federal securities laws. 

(f) Non-Contravention. No consent, approval, order or authorization of, or registration, qualification, designation, declaration or
filing with, any federal, state or local governmental authority on the part of the Company is required in connection with the consummation of the sale and issuance of Shares contemplated by this Agreement, except for the filing of notices of the
sale of Shares pursuant to Regulation D promulgated under the Securities Act and applicable state securities laws. The Company is not in violation or default (a) of any provision of its certificate of incorporation or articles of association,
or (b) in any material respect of any provision of (i) any instrument, judgment, order, writ or decree to which it is a party or by which it is bound, or (ii) any federal or state statute, rule or regulation applicable to the Company.
The execution, delivery and performance of this Agreement and the consummation of the transactions contemplated hereby will not result in any such violation or constitute, with or without the passage of time and giving of notice, either (i) a
default in any material respect of any such instrument, judgment, order, writ or decree or (ii) an event that results in the creation of any lien, charge or encumbrance upon any assets of the Company or the suspension, revocation, impairment,
forfeiture, or nonrenewal of any material permit, license, authorization or approval applicable to the Company. 
 4.
REPRESENTATIONS AND WARRANTIES OF SUBSCRIBER. 
 4.1 Requisite Power and Authority. Subscriber has all necessary corporate power
and authority to execute and deliver this Agreement and to carry out its provisions. All corporate action on Subscriber’s part required for the lawful execution and delivery of this Agreement has 

  
 CRIPSR Therapeutics -
Participation Agreement 
 5 

 
been taken. Upon its execution and delivery, this Agreement will be a valid and binding obligation of Subscriber, enforceable in accordance with its terms, except (a) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights, and (b) as limited by general principles of equity that restrict the availability of equitable
remedies. 
 4.2 Closing Date Representations. On the Closing Date, Subscriber hereby represents and warrants to the Company as
follows: 
 (a) Requisite Power and Authority. Subscriber has all necessary corporate power and authority to carry out its provisions.
This Agreement constitutes a valid and binding obligation of Subscriber, enforceable in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application
affecting enforcement of creditors’ rights, and (b) as limited by general principles of equity that restrict the availability of equitable remedies. 

(b) Investment Representations. Subscriber understands that the Shares have not been registered under the Securities Act. Subscriber
also understands that the Shares are being offered and sold pursuant to an exemption from registration contained in the Securities Act based in part upon Subscriber’s representations contained in this Agreement. Subscriber hereby represents and
warrants as follows: 
 (i) Subscriber Bears Economic Risk. Subscriber has substantial experience in evaluating and
investing in private placement transactions of securities in companies similar to the Company so that it is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own interests. Subscriber
must bear the economic risk of this investment indefinitely unless the Shares are registered pursuant to the Securities Act, or an exemption from registration is available. Subscriber understands that the Company has no present intention of
registering the Shares or any other securities issued in respect of the Shares upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event. Subscriber also understands that there is no assurance that any exemption
from registration under the Securities Act will be available and that, even if available, such exemption may not allow Subscriber to transfer all or any portion of the Shares under the circumstances, in the amounts or at the times Subscriber might
propose. 
 (ii) Acquisition for Own Account. Subscriber is acquiring the Shares for Subscriber’s own account for
investment only, and not with a view towards their distribution. 
 (iii) Subscriber Can Protect Its Interest.
Subscriber represents that by reason of its, or of its management’s, business or financial experience, Subscriber has the capacity to protect its own interests in connection with the transactions contemplated in this Agreement. Further,
Subscriber is aware of no publication of any advertisement in connection with the transactions contemplated in this Agreement. 

(iv) Accredited Investor. Subscriber represents that it is an accredited investor within the meaning of Regulation D under the
Securities Act. 

  
 CRIPSR Therapeutics -
Participation Agreement 
 6 

 (v) Foreign Investors. If Subscriber is not a
United States person (as defined by Section 7701(a)(30) of the Internal Revenue Code of 1986, as amended) (a “Foreign Subscriber”), Subscriber has satisfied itself as to the full observance of the laws of its
jurisdiction in connection with any invitation to subscribe for the Shares or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the subscription of the Shares, (ii) any foreign exchange
restrictions applicable to such subscription, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the subscription, holding, redemption,
sale or transfer of the Shares. Subscriber’s subscription and payment for and continued beneficial ownership of the Shares, will not violate any applicable securities or other laws of Subscriber’s jurisdiction. 

(vi) Company Information. Subscriber has received and read the Company’s financial statements and has had an opportunity to
discuss the Company’s business, management and financial affairs with directors, officers and management of the Company and has had the opportunity to review the Company’s operations and facilities. Subscriber has also had the opportunity
to ask questions of and receive answers from, the Company and its management regarding the terms and conditions of this investment. 

(vii) Rule 144. Subscriber acknowledges and agrees that the Shares are “restricted securities” as defined in Rule 144
promulgated under the Securities Act as in effect from time to time and must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. Subscriber has been advised or is
aware of the provisions of Rule 144, which permits limited resale of securities subscribed for in a private placement subject to the satisfaction of certain conditions, including, among other things: the availability of certain current public
information about the Company, the resale occurring following the required holding period under Rule 144 and the number of securities being sold during any three-month period not exceeding specified limitations. 

(viii) Residence. The office or offices of Subscriber in which its investment decision was made is located at the address or
addresses of Subscriber set forth on the signature page hereof. 
 (ix) “Bad Actor”
Status. Subscriber hereby represents that neither it nor any of its Rule 506(d) Related Parties (as defined below) is a “bad actor” within the meaning of 506(d) promulgated under the Securities Act. For purposes of this
Agreement, “Rule 506(d) Related Party” shall mean a person or entity covered by the “Bad Actor disqualification” provision of Rule 506(d) of the Securities Act. 

(c) Transfer Restrictions. Subscriber acknowledges and agrees that the Shares are subject to restrictions on transfer. 

(d) Legends. Subscriber understands and agrees that the certificates or confirmations evidencing or confirming the Shares, or any other
securities issued in respect of the Shares upon any stock split, stock dividend, recapitalization, merger, consolidation or similar event, shall bear the legends required by this Agreement, including legends relating to restrictions on transfer
under federal and state securities laws (as set forth below) and legends required under applicable state securities laws. 

  
 CRIPSR Therapeutics -
Participation Agreement 
 7 

 “THE SHARES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO AND COMPLIANCE WITH APPLICABLE STATE
SECURITIES LAWS OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933 OR APPLICABLE STATE SECURITIES LAWS.” 

5. CONDITIONS TO CLOSING. 

5.1 Conditions to Subscriber’s Obligations at the Closing. Subscriber’s obligations to subscribe for the Shares at the Closing
are subject to the satisfaction (or waiver by Subscriber), at or prior to the Closing Date, of the following conditions: 
 (a)
Representations and Warranties True; Performance of Obligations. The representations and warranties made by the Company in Section 3 hereof shall be true and correct in all respects as of the Closing Date, except in each case, for those
representations and warranties that address matters only as of a particular date, which shall be true and correct in all respects as of such date, and the Company shall have performed all obligations and conditions herein required to be performed or
observed by it at or prior to the Closing Date. 
 (b) Stockholder Approval. The Company shall have adopted the additional
Article 3octies in Exhibit 2 and the authorization pursuant to such Article shall not have expired or the Company shall have procured otherwise the necessary stockholder approval to the
extent required by Swiss Law, its articles of association as then in effect (the “Charter”), and any voting or other agreement among the stockholders and the Company for the approval of the transactions
contemplated by this Agreement, including any amendment of the Charter. 
 (c) Legal Investment. On the Closing Date, the sale
and issuance of the Shares shall be legally permitted by all laws and regulations to which Subscriber and the Company are subject. 

(d) Consents, Permits, and Waivers. The Company shall have obtained any and all consents, permits and waivers necessary or appropriate
for consummation of the transactions contemplated by this Agreement, except for any such consents, permits and waivers as may be properly obtained subsequent to the Closing. 

(e) Compliance Certificate. The Company shall have delivered to Subscriber a compliance certificate, executed by the President of the
Company, dated as of the Closing Date, to the effect that the conditions specified in subsections (a), (b) and (g) of this Section 5.1 have been satisfied. 

  
 CRIPSR Therapeutics -
Participation Agreement 
 8 

 (f) Secretary’s Certificate. At the Closing, Subscriber shall have received from the
Company’s Secretary a certificate having attached thereto (i) the Charter as resolved by the Shareholders’ Meeting and the Board of Directors at the time of the Closing, (ii) resolutions approved by the Board of Directors of the
Company authorizing the transactions contemplated hereby, and (iii) resolutions approved by the Company’s stockholders in accordance with Section 5.1(b) above. 

(g) IPO Closing. All conditions to the closing of the IPO set forth in the Underwriting Agreement shall have been satisfied or waived
and the IPO shall be simultaneously closing. 
 (h) Opinion of Counsel. Counsel to the Company shall have delivered to
Subscriber an opinion, which opinion shall cover the exemption from the registration requirements of the Securities Act of 1933 and such other matters as are customarily included in opinions relating to like transactions. 

(i) License Rights. The Company shall have provided Evidence Related to Global Filings as provided by the JV Agreement. 

5.2 Conditions to Obligations of the Company. The Company’s obligation to issue and sell the Shares to Subscriber at the Closing is
subject to the satisfaction (or waiver by the Company), on or prior to the Closing Date, of the following conditions: 
 (a)
Representations and Warranties True. The representations and warranties in Section 4 made by Subscriber shall be true and correct in all respects as of the Closing Date. 

(b) Performance of Obligations. Subscriber shall have performed and complied with all agreements and conditions herein required to be
performed or complied with by Subscriber on or before the Closing Date. 
 (c) Consents, Permits, and Waivers. The Company
shall have obtained any and all consents, permits and waivers necessary or appropriate for consummation of the transactions contemplated by this Agreement. 

6. STANDSTILL. 

6.1 Restrictions. Except with the written consent of the Company (which may be withheld by the Company in its sole
discretion), Subscriber agrees during the period from the closing of the IPO until the later to occur of (i) the eighteen month anniversary of the closing of the IPO, or (ii) upon termination of the JV Agreement, neither it nor any of its
Affiliates (as such term is defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), shall: 

(a) acquire, directly or indirectly, any equity securities of the Company if such acquisition would increase Subscriber’s
beneficial ownership percentage of the Company’s equity securities by more than 5% above the Subscriber’s beneficial ownership percentage of the Company’s equity securities immediately upon consummation of the IPO (and

  
 CRIPSR Therapeutics -
Participation Agreement 
 9 

 
giving effect to the subscription of Shares pursuant to this Agreement) as calculated pursuant to Regulation 13D-G of the Exchange Act (the “Ownership Cap”); provided that any increase
in percentage ownership beyond the Ownership Cap due solely to actions of the Company shall not be a violation of this restriction; 

(b) propose (i) any merger, consolidation, business combination, tender or exchange offer, sale of all
or substantially all of the Company’s assets or businesses, or similar transactions involving the Company (each a “Business Combination”) or (ii) any recapitalization, restructuring, liquidation or other
extraordinary transaction with respect to the Company; 
 (c) (i) propose or seek, whether alone or in concert with
others, any “solicitation” (as such term is used in the rules of the Securities and Exchange Commission (the “SEC”)) of proxies or consents to vote any securities of the Company, (ii) nominate any person as a
director of the Company, (iii) propose any matter to be voted upon by the stockholders of the Company, or (iv) act, alone or in concert with others, to seek to control the management, Board of Directors of the Company, policies or affairs
of the Company; 
 (d) directly or indirectly, form, join or in any way participate in a third party “group” (as such term
is used in the rules of the SEC) (or discuss with any third party the potential formation of a group) with respect to any securities of the Company; 

(e) deposit any equity securities of the Company in a voting trust or subject any equity securities of the Company to any arrangement or
agreement with respect to the voting of such equity securities of the Company; or 
 (f) enter into discussions, negotiations,
arrangements or agreements with any person or entity relating to the foregoing actions referred to in (a) through (e) above. 
 6.2
Termination of Restrictions. The restrictions of Section 6.1 shall 
 (a) terminate automatically upon (i) the Company
(X) publicly announcing that it has entered into a definitive agreement with a third party to effect a Business Combination, (Y) publicly announcing the Company’s or its Board of Directors’ approval or recommendation of any
Business Combination or (Z) filing bankruptcy proceedings, making an assignment for the benefit of creditors or entering into a receivership, or the Company having filed against it bankruptcy proceedings that are not dismissed within sixty
(60) days after commencement, (xx) waiving the application of any provision of a standstill agreement with any other person with respect to the Company’s equity securities; (yy) publicly announcing a possible sale of all or
substantially all of the assets of the Company in one or more transactions, or (ii) any third party commencing a tender offer or exchange offer to acquire beneficial ownership of more than 25% of the Company’s equity securities. 

(b) terminate and be of no further force or effect immediately prior to the consummation of a liquidation, dissolution or winding up of
the Company, or a Business Combination. 

  
 CRIPSR Therapeutics -
Participation Agreement 
 10 

 (c) not prevent Subscriber or its Affiliates from acquiring any company which holds, or is
interested in, any equity securities in the Company except where the principal reason for the acquisition is to acquire an interest in the equity securities in the Company; or 

(d) not prevent Subscriber or its Affiliates (the “Bayer Group”) from acquiring any
equity securities of the Company by or through (i) a diversified mutual or pension fund managed by an independent investment adviser or pension plan established for the benefit of Subscriber or its Affiliates’ employees and managed by an
independent investment advisor or independent trustee, (ii) any of the employee benefit plans of a member of Bayer Group for which investment decisions are made by an independent trustee, or (iii) any portfolio not controlled or managed by
any member of the Bayer Group which invests in the Company’s equity securities among other companies. 
 (e) For
purposes of this Section 6, the terms, “beneficial ownership” and “equity securities” shall be as defined under Regulation 13D-G of the Exchange Act. 

6.3 Lock-up Agreement. Subscriber agrees that it shall enter into a lock-up agreement with the underwriters for the IPO in a form
substantially similar to the lock-up agreement entered into by the Company’s directors, executive officers and 5% stockholders, which shall cover all shares of the Company’s capital stock held by Subscriber, which for the sake of clarity
shall include the shares issued upon conversion of the securities issued pursuant to the Convertible Loan Agreement dated on or around December 16, 2015, and the Shares subscribed for pursuant to this Agreement. The underwriters in connection
with the IPO are intended third party beneficiaries of this Section 6.2 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

7. Covenants. Until the Closing (in the case of Section 7.1 and 7.2) and from and after the Closing Date (in the case of
Section 7.3 and 7.4): 
 7.1 Alternative IPO Entities. In the event that the Company elects to effect the IPO with equity
securities of any subsidiary or new parent of the Company (collectively, “Alternative IPO Entities”) rather than the equity securities of the Company, whether as a result of a reorganization of the Company or otherwise,
Subscriber and the Company shall cause the Alternative IPO Entity to enter into an agreement with Subscriber that provides Subscriber with rights with respect to the equity securities of the Alternative IPO Entity that are substantially the same as,
and in any event no less favorable in the aggregate to, the rights provided to Subscriber in this Agreement. 
 7.2 IPO Outside the United
States. In the event the IPO is made in a jurisdiction other than the United States, the Company shall enter into an agreement with Subscriber providing Subscriber, under the laws of such jurisdiction, the rights granted to Subscriber under this
Agreement. 
 7.3 Registration Rights. The Registration Rights Agreement in Annex 19.8 of the Shareholders’ Agreement (the
“Registration Rights Agreement”) regulates the registration rights of the shareholders of the Company. On or prior to the Closing Date, the same registration rights 

  
 CRIPSR Therapeutics -
Participation Agreement 
 11 

 
as conferred to the Preferred Shares (as defined in the Shareholders’ Agreement) pursuant to the Registration Rights Agreement shall be granted to the Subscriber with respect to the Shares
and such registration rights shall survive the Closing Date in accordance with the terms of the Shareholders’ Agreement. 
 7.4
Reports Under Exchange Act. With a view to making available to Subscriber the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit Subscriber to sell securities of the Company to the public without
registration or pursuant to a registration on Form S 3, the Company shall at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO: 

(a) make and keep available at all times adequate current public information, as those terms are understood and defined in SEC Rule 144;

 (b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the
Company under the Securities Act and the Exchange Act; and 
 (c) furnish to Subscriber, so long as Subscriber owns any Registrable
Securities (as defined in the Registration Rights Agreement in Annex 19.8 of the Shareholders’ Agreement), forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting
requirements of SEC Rule 144 (at any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities Act, and the Exchange Act, or that it qualifies as a registrant whose
securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies) and (ii) such other information as may be reasonably requested in availing Subscriber of any rule or regulation of the SEC that permits the selling of
any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act). 

8. MISCELLANEOUS. 
 8.1
Confidentiality. Article 17 of the Joint Venture Agreement shall apply mutatis mutandis even if the Joint Venture Agreement is terminated. 

8.2 Costs and Expenses. Each Party shall bear its own costs and expenses in connection with negotiation of this Subscription Agreement.

 8.3 Governing Law. This Subscription Agreement and any questions related thereto shall be subject to the laws of Switzerland
excluding its conflict of law rules, unless otherwise stated herein with respect to U.S. securities laws. 
 8.4 Jurisdiction. The
ordinary courts at the place of the registered offices of the Company shall have exclusive jurisdiction with regard to any dispute arising between the Parties out or in connection with this Subscription Agreement (including a dispute regarding the
construction and validity thereof). 

  
 CRIPSR Therapeutics -
Participation Agreement 
 12 

 8.5 Foreign Exchange Rates. To the extent necessary to accomplish the goals of this
agreement, any currency conversion (i.e., CHF to USD) shall be calculated by making use of the Reference Exchange Rate as of the applicable date of determination. “Reference Exchange Rate” shall mean the currency exchange rate (i) as
published by the European Central Bank two (2) Business Days prior to the respective payment date, or (ii) if no rates are published on that day, on the latest day for which such rates are published, or (iii) if the European Central
Bank generally does not publish such reference exchange rate for the respective currency, as published on the internet page of the Financial Times for such day or the latest day before that day for which such rates are published, whatever the case
may be. 
 8.6 Survival. The representations and warranties of the Company and Subscriber contained in or made pursuant to this
Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of Subscriber or the Company. 

8.7 Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the respective
successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies, obligations, or liabilities
under or by reason of this Agreement, except as expressly provided in this Agreement. Neither the Company nor Subscriber shall not have the right to assign this Agreement without the prior written consent of the other party; provided, however, that
Subscriber may assign its rights and obligations under this Agreement to any other member of the corporate group of which it is a member. 

8.8 Entire Agreement. This Agreement constitutes the full and entire understanding and agreement between the parties with regard to the
subjects hereof and thereof and no party shall be liable for or bound to any other in any manner by any oral or written representations, warranties, covenants and agreements except as specifically set forth herein and therein. 

8.9 Severability. In the event one or more of the provisions of this Agreement should, for any reason, be held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if such invalid, illegal or unenforceable provision had never been
contained herein. Upon such determination that any term or other provision is invalid, illegal or unenforceable, the parties hereto shall negotiate in good faith to modify this Agreement so as to effect the original intent of the parties as closely
as possible in a mutually acceptable manner in order that the transactions contemplated hereby be consummated as originally contemplated to the greatest extent possible. 

8.10 Amendment and Waiver. This Agreement may be amended or modified, and the rights and the obligations of the Company and the rights
and obligations of Subscriber may be waived, only upon the written consent of the Company and Subscriber. 
 8.11 Delays or Omissions.
It is agreed that no delay or omission to exercise any right, power or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement, shall impair any such right, power or remedy, nor shall it be 

  
 CRIPSR Therapeutics -
Participation Agreement 
 13 

 
construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or waiver of or acquiescence in any similar breach, default or noncompliance thereafter
occurring. It is further agreed that any waiver, permit, consent or approval of any kind or character on any party’s part of any breach, default or noncompliance under this Agreement or any waiver on such party’s part of any provisions or
conditions of this Agreement must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies afforded to a party under this Agreement shall be cumulative and not alternative. 

8.12 Notices. All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon
personal delivery to the party to be notified, (b) when sent by electronic mail confirmed by registered mail if the e-mail is sent during normal business hours of the recipient, if not, then on the next Business Day, (c) five (5) days
after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day for domestic deliveries and two (2) days for international deliveries after deposit with a recognized courier,
specifying the appropriate type of delivery, with written verification of receipt. All communications shall be sent to the Company and to Subscriber at the applicable address as set forth below or at such other address or as the Company or
Subscriber may designate by ten (10) days advance written notice to the other party hereto. 
  

			
	To the Company:	  	CRISPR Therapeutics AG
		  	Aeschenvorstadt 36
		  	4051 Basel
		  	Switzerland
		  	Attention: Chief Executive Officer
		
		  	and
		
		  	CRISPR Therapeutics, Inc.
		  	675 W Kendall St,
		  	Cambridge, MA 02142
		  	USA
		  	Attention: Chief Financial Officer
		
	With a copy to:	  	VISCHER AG
		  	Aeschenvorstadt 4
		  	CH 4051 Basel,
		  	Switzerland
		  	Attention: Matthias Staehelin
		
		  	and
		
		  	Goodwin Procter LLP
		  	Exchange Place
		  	53 State Street
		  	Boston, MA 02109
		  	USA
		  	Attention: Mitchell S. Bloom and Robert E. Puopolo

  
 CRIPSR Therapeutics -
Participation Agreement 
 14 

			
	To Subscriber:	  	Bayer Aktiengesellschaft
		  	Kaiser-Wilhelm-Allee
		  	51368 Leverkusen
		  	Germany
		  	Attention: Dr. Axel Bouchon and Dr. Jan Heinemann
		
	With a copy to:	  	Walder Wyss AG
		  	Aeschenvorstadt 48
		  	P.O. Box 633
		  	CH 4010 Basel
		  	Switzerland
		  	Attention: Alexander Gutmans
		
		  	and
		
		  	Norton Rose Fulbright
		  	801 Pennsylvania Avenue, N.W.
		  	Washington, D.C. 20004-2623
		  	USA
		  	Attention: Marilyn Mooney

 8.13 Titles and Subtitles. The titles of the sections and subsections of this Agreement are for
convenience of reference only and are not to be considered in construing this Agreement. 
 8.14 Counterparts. This Agreement may be
executed in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. Any or all parties may execute this Agreement by facsimile signature or scanned signature in PDF format and any
such facsimile signature or scanned signature, if identified, legible and complete, shall be deemed an original signature and each of the parties is hereby authorized to rely thereon. 

8.15 Broker’s Fees. Each party hereto represents and warrants that no agent, broker, investment banker, person or firm acting on
behalf of or under the authority of such party hereto is or will be entitled to any broker’s or finder’s fee or any other commission directly or indirectly in connection with the transactions contemplated herein. Each party hereto further
agrees to indemnify each other party for any claims, losses or expenses incurred by such other party as a result of the representation in this Section 8.16 being untrue. 

8.16 Pronouns. All pronouns contained herein, and any variations thereof, shall be deemed to refer to the masculine, feminine or
neutral, singular or plural, as to the identity of the parties hereto may require. 
 8.17 No Commitment for Additional Financing. The
Company acknowledges and agrees that Subscriber has not made any representation, undertaking, commitment or agreement to provide or assist the Company in obtaining any financing, investment or other assistance, other than the subscription of the
Shares as set forth herein and that certain Convertible Loan Agreement dated on or around December 16, 2015 and subject to the conditions set forth herein and therein. In addition, the Company acknowledges and agrees that (i) no
statements, whether 

  
 CRIPSR Therapeutics -
Participation Agreement 
 15 

 
written or oral, made by Subscriber or its representatives on or after the date of this Agreement shall create an obligation, commitment or agreement to provide or assist the Company in obtaining
any financing or investment, (ii) the Company shall not rely on any such statement by Subscriber or its representatives and (iii) an obligation, commitment or agreement to provide or assist the Company in obtaining any financing or
investment may only be created by a written agreement, signed by Subscriber and the Company, setting forth the terms and conditions of such financing or investment and stating that the parties intend for such writing to be a binding obligation or
agreement. Subscriber shall have the right, in its sole and absolute discretion, to refuse or decline to participate in any other financing of or investment in the Company, and shall have no obligation to assist or cooperate with the Company in
obtaining any financing, investment or other assistance. 
 8.18 No Waiver. The failure of any Party to enforce any of the provisions
of this Subscription Agreement or any rights with respect thereto shall in no way be considered as a waiver of such provisions or rights or in any way to affect the validity of this Subscription Agreement. The waiver of any breach of this
Subscription Agreement by any Party hereto shall not be construed as a waiver of any other prior or subsequent breach. 
 8.19
Termination. 
 (a) The Parties hereto may terminate this Agreement by mutual written agreement. 

(b) Either Party may terminate this Agreement by providing written notice to the other Party if any party to the JV Agreement has
provided written notice of the termination of the JV Agreement to the other party. 
 (c) At any time
prior to the Event Date, Subscriber may (i) terminate this Agreement by providing written notice to the Company if the Company has not provided Evidence Related to Global Filings as required by the JV Agreement, (ii) irrevocably and
unconditionally waive the condition to closing set forth in Section 5.1(i) by providing written notice to the Company, or (iii) take no action. At least fifteen (15) Business Days prior to the date that the Company anticipates the
initial filing (including confidential submissions) of the Registration Statement relating to the IPO, the Company shall provide written notice to the Subscriber of such anticipated filing date (the “Event Date Notice”). The
tenth Business Day after the delivery of such notice shall be the “Event Date”. 
 (d) Either
Party may, at its sole discretion, terminate this Agreement by providing written notice to the other Party if the Closing has not occurred by June 30, 2017. 

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 CRIPSR Therapeutics -
Participation Agreement 
 16 

 IN WITNESS WHEREOF, the parties hereto have executed this Subscription Agreement as of the date first set
forth above. 
  

									
	COMPANY:	  		  	SUBSCRIBER:
	CRISPR Therapeutics AG	  		  	Bayer Global Investments B.V.
					
	Signature:	  	 /s/ Rodger Novak
	  		  	Signature:	  	 /s/ C.H.A. Koersvelt

	Print Name:	  	Rodger Novak	  		  	Print Name:	  	C.H.A. Koersvelt
	Title:	  	CEO	  		  	Title:	  	Managing Director
					
		  		  		  	Signature:	  	 /s/ A. Steiger-Bagel

		  		  		  	Print Name:	  	A. Steiger-Bagel
		  		  		  	Title:	  	Managing Director

 [Signature Page Subscription Agreement] 

 Exhibit 1: Subscription Form 

 

 
 SUBSCRIPTION AND REGISTRATION FORM 

Subscription Rights and Shares may not be offered or sold, directly or indirectly, in or from any country or jurisdiction except under circumstances that
will result in compliance with any applicable rules and regulations of any such country or jurisdiction. This security offering is in the United States solely addressed to accredited investors (as defined in Regulation D of the Securities Act) and
in the European Union solely addressed to qualified investors or to special category of investors (as defined in article 2 section 1 E of the Prospectus Directive). 

Making reference to the authorized share capital in Art. 3octies of the articles of association of Crispr
Therapeutics AG, with registered seat in Basel, company number CHE-494.642.722 (the “Company”), as enacted by the extraordinary general meeting held [DATE] and a meeting of the Board of Directors held on or around [DATE] to increase the
share capital of the Company by the aggregate amount of CHF[AMOUNT] from CHF [AMOUNT] up to CHF [AMOUNT] through the issuance of up to [AMOUNT] new common shares (the “Common Shares” and each a “Common Share”) with a nominal
value of CHF [AMOUNT] each at the subscription amount of USD [AMOUNT], per share payable in cash at issuance. 
 For my/our commitment I/we hereby
unconditionally subscribe                     (in words
                    ) Common Shares with the irrevocable and unconditional undertaking to pay the issue price of USD [AMOUNT] for each allotted
Common Share to the Company. 
 I/we grant power of attorney to each member of the board of directors of the Company to repeat the subscription of based on
a signed copy of this form. 
 I/we confirm the following: (1) My/our overall commitment to investments that are not readily marketable is reasonable
in relation to my/our net worth; (2) I am/we are willing and able to bear the economic risk of this investment; and (3) I am/we are purchasing the shares offered for my/our own account for investment purposes only and not with a view to
distribution or resale. 
 I/we confirm that I/we have taken note of the contents of the Articles of Association of the Company as resolved on [DATE]. 

I/we declare that I/we will acquire Common Shares 

            in my/our own name and for my/our own account; 

            as a trustee (nominee) for the following person 

Name: 

 Address: 
 I /we
confirm that I/we are not acquiring the Shares for the account or benefit of another person who is a U.S. person or resident in China, Australia, Canada, Taiwan or Japan. 

I/we request that the Common Shares be entered into the shareholders’ register of Crispr Therapeutics AG under my/our name as follows: 

Individuals 

 ̈ Mr  ̈ Ms/Mrs 

 

			
	Name	  	First Name:
	Street, No.:	  	
	Postal Code, City:	  	Country:
	Telefon, No.:	  	Fax, No. or e-mail:
	Nationality:	  	Date of Birth:

 Legal Entities 
  

			
	Street, No.:	  	
	Postal Code, City:	  	Country:
	Telefon, No.:	  	Fax, No. or e-mail: +
	Legal Status:	  	Line of Business:
	Activity/Purpose:	  	Jurisdiction of Incorporation:
		  	

 If I am a U.S. Person as defined in Regulation S (see on the form below), I/we confirm I am/we are an accredited
investor(s) as that term is defined in Regulation D of the Securities Act (see at the end of this form), the Common Shares have not been offered for sale to me/us in the United States, and I am/we are not acquiring the Shares for the account or
benefit of any other U.S. person. 
 If I am /we are a resident of a members state of the European Union, I/we understand that the offering is solely
addressed to qualified investors or to special category of investors (as defined in article 2 section 1 E of the Prospectus Directive, see below) and that any subscription by another person may not be permitted and must be approved by the Company.

 Allocation and Payment 
 I/we will wire the
amount of USD [AMOUNT]for each Common Shares allotted to me/us with value date [DATE] to the following escrow bank account: 
 Name of bank: XXX, for
further credit to XXX, SWIFT: XXX, Beneficiary/Formal account holder: Crispr Therapeutics AG, Basel; Account Number USD: IBAN CHXXX 

  
 CRIPSR Therapeutics -
Participation Agreement 
 20 

 Stamp Duties / Dividends 

The stamp tax (“Emissionsabgabe”) will be borne by Crispr Therapeutics AG. The Shares are entitled to dividends starting with the business year
[DATE]. 
 Governing Law and Jurisdiction 
 This
Subscription and Registration Form and any questions related thereto shall be subject to the laws of Switzerland excluding its conflict of law rules. The ordinary courts at the place of the registered offices of the Company shall have exclusive
jurisdiction with regard to any dispute arising between the Parties out or in connection with this Subscription and Registration (including a dispute regarding the construction and validity thereof). 

 

			
	Place/Date:                                    
	  	Signature:                                    
    

 [signature does not need be notarized] 

U.S. Securities Act of 1933: Definition of U.S. Person / Accredited Investor. 

As used in Regulation S, the term “U.S. person” means: 

(i) any natural person resident in the United States; 
 (ii) any
partnership or corporation organized or incorporated under the laws of the United States; 
 (iii) any estate of which any executor or administrator is a
U.S. person; 
 (iv) any trust of which any trustee is a U.S. person; 

(v) any agency or branch of a foreign entity located in the United States; 

(vi) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S.
person; 
 (vii) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or
(if an individual) resident in the United States; and 
 (viii) any partnership or corporation if: (A) organized or incorporated under the laws of any
foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a),
which is codified in Title 17 of the US Code of Federal Regulations as § 230.501) who are not natural persons, estates or trusts. 
 As used in
Regulation D, accredited investor shall mean any person who comes within any of the following categories, or who the issuer reasonably believes comes within any of the following categories, at the time of the sale of the securities to that person:

  

	 	1.	Any bank as defined in section 3(a)(2) of the Act, or any savings and loan association or other institution as defined in section 3(a)(5)(A) of the Act whether acting in its individual or fiduciary capacity; any broker
or dealer registered pursuant to section 15 of the Securities Exchange Act of 1934; any insurance company as defined in section 2(a)(13) of the Act; any investment company registered under the Investment Company Act of 1940 or a business development
company as defined in section 2(a)(48) of that Act; any Small Business Investment Company licensed by the U.S. Small Business Administration under section 301(c) or (d) of the Small Business Investment Act of 1958; any plan established and
maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such plan has total assets in excess of $5,000,000; any employee benefit plan within
the meaning of the Employee Retirement Income Security Act of 1974 if the investment decision is made by a plan fiduciary, as defined in section 3(21) of such act, which is either a bank, savings and loan association, insurance company, or
registered investment adviser, or if the employee benefit plan has total assets in excess of $5,000,000 or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors; 

  
 CRIPSR Therapeutics -
Participation Agreement 
 21 

	 	2.	Any private business development company as defined in section 202(a)(22) of the Investment Advisers Act of 1940; 

  

	 	3.	Any organization described in section 501(c)(3) of the Internal Revenue Code, corporation, Massachusetts or similar business trust, or partnership, not formed for the specific purpose of acquiring the securities
offered, with total assets in excess of $5,000,000; 

  

	 	4.	Any director, executive officer, or general partner of the issuer of the securities being offered or sold, or any director, executive officer, or general partner of a general partner of that issuer; 

 

	 	5.	Any natural person whose individual net worth, or joint net worth with that person’s spouse, at the time of his purchase exceeds $1,000,000 excluding the value of the primary residence of such person;

  

	 	i.	Except as provided in paragraph ii. below, for purposes of calculating net worth: 

  

	 	a.	The person’s primary residence shall not be included as an asset; 

  

	 	b.	Indebtedness that is secured by the person’s primary residence, up to the estimated fair market value of the primary residence at the time of the sale of securities, shall not be included as a liability (except
that if the amount of such indebtedness outstanding at the time of sale of securities exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of the primary residence, the amount of such excess shall be
included as a liability); and 

  

	 	c.	Indebtedness that is secured by the person’s primary residence in excess of the estimated fair market value of the primary residence at the time of the sale of securities shall be included as a liability;

  

	 	ii.	Paragraph i. above will not apply to any calculation of a person’s net worth made in connection with a purchase of securities in accordance with a right to purchase such securities, provided that:

  

	 	a.	Such right was held by the person on July 20, 2010; 

  

	 	b.	The person qualified as an accredited investor on the basis of net worth at the time the person acquired such right; and 

  

	 	c.	The person held securities of the same issuer, other than such right, on July 20, 2010. 

  

	 	6.	Any natural person who had an individual income in excess of $200,000 in each of the two most recent years or joint income with that person’s spouse in excess of $300,000 in each of those years and has a reasonable
expectation of reaching the same income level in the current year; 

  

	 	7.	Any trust, with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the securities offered, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) and

  

	 	8.	Any entity in which all of the equity owners are accredited investors. 

  
 CRIPSR Therapeutics -
Participation Agreement 
 22 

 European Union: Prospectus Directive 2010/73/EU of 24 November 2010 

Article 2 - Definitions 
 1. For the purposes of this Directive,
the following definitions shall apply: 
  

	(a)	- (d) [...]; 

  

	 	(e)	‘qualified investors’ means persons or entities that are described in points (1) to (4) of Section I of Annex II to Directive 2004/39/EC of the European Parliament and of the Council of 21 April
2004 on markets in financial instruments1, and persons or entities who are, on request, treated as professional clients in accordance with Annex II to Directive 2004/39/EC2, or recognized as eligible counterparties in accordance with Article 24 of Directive 2004/39/EC unless they have requested that they be treated as non-professional clients. Investment firms and
credit institutions shall communicate their classification on request to the issuer without prejudice to the relevant legislation on data protection. Investment firms authorized to continue considering existing professional clients as such in
accordance with Article 71(6) of Directive 2004/39/EC shall be authorized to treat those clients as qualified investors under this Directive. 

  

	 	 	

  

	1 	(1) Entities which are required to be authorized or regulated to operate in the financial markets. The list below should be understood as including all authorized entities carrying out the characteristic activities
of the entities mentioned: entities authorized by a Member State under a Directive, entities authorized or regulated by a Member State without reference to a Directive, and entities authorized or regulated by a non-Member State: 

 
  

	 	(a)	Credit institutions 

  

	 	(b)	Investment firms 

  

	 	(c)	Other authorized or regulated financial institutions 

  

	 	(d)	Insurance companies 

  

	 	(e)	Collective investment schemes and management companies of such schemes 

  

	 	(f)	Pension funds and management companies of such funds 

  

	 	(g)	Commodity and commodity derivatives dealers 

  

	 	(h)	Locals 

  

	 	(i)	Other institutional investors 

 (2) Large undertakings meeting two of the following size requirements on a
company basis: 
  

	 	—	balance sheet total: EUR 2 0 000 000, 

  

	 	—	net turnover: EUR 4 0 000 000, 

  

	 	—	own funds: EUR 2 000 000. 

 (3) National and regional governments, public bodies that manage public debt,
Central Banks, international and supranational institutions such as the World Bank, the IMF, the ECB, the EIB and other similar international organizations. 

(4) Other institutional investors whose main activity is to invest in financial instruments, including entities dedicated to the securitization of assets or
other financing transactions. 
  

	2 	Clients other than those mentioned in section I, including public sector bodies and private individual investors, may also be allowed to waive some of the protections afforded by the conduct of business rules.
Investment firms should therefore be allowed to treat any of the above clients as professionals provided the relevant criteria and procedure mentioned below are fulfilled. These clients should not, however, be presumed to possess market knowledge
and experience comparable to that of the categories listed in section I. Any such waiver of the protection afforded by the standard conduct of business regime shall be considered valid only if an adequate assessment of the expertise, experience and
knowledge of the client, undertaken by the investment firm, gives reasonable assurance, in light of the nature of the transactions or services envisaged, that the client is capable of making his own investment decisions and understanding the risks
involved. The fitness test applied to managers and directors of entities licensed under Directives in the financial field could be regarded as an example of the assessment of expertise and knowledge. In the case of small entities, the person subject
to the above assessment should be the person authorized to carry out transactions on behalf of the entity. In the course of the above assessment, as a minimum, two of the following criteria should be satisfied: 

 

	 	—	the client has carried out transactions, in significant size, on the relevant market at an average frequency of 10 per quarter over the previous four quarters, 

	 	—	the size of the client’s financial instrument portfolio, defined as including cash deposits and financial instruments exceeds EUR 500 000, 

	 	—	the client works or has worked in the financial sector for at least one year in a professional position, which requires knowledge of the transactions or services envisaged. 

  
 CRIPSR Therapeutics -
Participation Agreement 
 23 

 Exhibit 2: Amendment to Articles of Association 

 

			
	 Art. 3octies Authorized Share Capital

 
 The Board of Directors is authorized, at any time until 30 June 2017 to increase the
share capital by a maximum of CHF 78’159.90 through the issuance of a maximum of 781’5993 registered shares, to be fully paid up, with a nominal value of CHF [AMOUNT] per share.
Increases by underwriting as well as partial increases are permissible. The issue price, the time of dividend entitlement, and the type of contribution will be determined by the Board of Directors. Upon acquisition, the new shares will be subject to
the transfer restrictions pursuant to Art. 6 of the Articles of Association.
	  	 Art. 3octies Genehmigtes Aktienkapital

 
 Der Verwaltungsrat ist ermachtigt, jederzeit bis zum 30 June 2017, das Aktienkapital
im Maximalbetrag von CHF 78’159.90 durch Ausgabe von hochstens 781’599 vollstandig zu liberierende Namenaktien mit einem Nennwert von je CHF 0.10 zu erhohen. Erhohungen auf dem Wege der Festubernahme sowie Erhohungen in Teilbetragen sind
gestattet. Der jeweilige Ausgabebetrag, der Zeitpunkt der Dividendenberechtigung und die Art der Einlagen werden vom Verwaltungsrat bestimmt. Nach dem Kauf unterliegen die neuen Namenaktien den Ubertragungsbeschrankungen gemass Art. 6 der
Statuten.

		
	The Board of Directors is authorized to exclude the pre-emptive right of shareholders if the newly issued registered shares (a) are at disposal as shares in the context of a pre-emptive rights offering in which more pre-emptive
rights are exercised than shares are at disposal, or (b) for the acquisition of companies, business units or participations through exchange of shares, or (c) for financing or refinancing of the acquisition of companies, business units or
participations or shares issuances in the framework of a collaboration and the fulfillment of participation rights granted in such context , or (d) for investment projects and/or investment vehicles which are applied in national or
international capital markets or for a quick and flexible raising of capital (including private placements) which probably could not be reached without the exclusion of the statutory pre-emptive right of the existing shareholders.	  	Der Verwaltungsrat ist ermachtigt, das Bezugsrecht der Aktionare auszuschliessen, wenn die neuen Namenaktien (a) im Rahmen eines Bezugsangebots, bei welchem mehr Bezugsrechte ausgeubt werden, als Aktien zur Verfugung stehen, zur
Zuweisung an bestehende Aktionare, oder (b) fur die Ubernahme von Unternehmungen, Unternehmensteilen oder Beteiligungen durch Aktientausch, oder (c) zur Finanzierung bzw. Refinanzierung des Erwerbs von Unternehmen, Unternehmensteilen oder
Beteiligungen fur die Ausgabe von Aktien im Rahmen einer Zusammenarbeit und der Erfullung von in diesem Zusammenhang eingegangen Beteiligungsrechten, oder (d) fur Investitionsvorhaben und/oder Instrumente, welche auf nationalen oder internationalen
Kapitalmarkten verwendet werden oder fur eine schnelle und flexible Kapitalaufnahme (einschliesslich Privatplatzierungen), die ohne Ausschluss des gesetzlichen Bezugsrechts der bestehenden Aktionare wahrscheinlich nicht erreicht werden
konnte.
		
	If pre-emptive rights have been granted but not exercised for registered shares, such shares must be used in the interest of the Company or must be sold at market conditions on the market.	  	Namenaktien, fur welche Bezugsrechte eingeraumt, aber nicht ausgeubt werden, sind im Interesse der Gesellschaft zu verwenden oder zu Marktkonditionen am Markt zu veraussern.

  

	3 	USD 35 million divided by 44.78EX-10.9

 Exhibit 10.9 

REGISTRATION RIGHTS AGREEMENT 

made as of June 10, 2016 
 by and
among 
 Hadley Harbor Master Investors (Cayman) L.P. 
 c/o
Wellington Management Company LLP 
 280 Congress Street Boston, MA 02210, USA 

(“Wellington”) 
 Franklin
Strategic Series – Franklin Biotechnology Discovery Fund 
 Franklin Advisers, Inc. 

One Franklin Parkway 
 San Mateo, CA 94403, USA 

(“Franklin Strategic”) 
 Franklin
Templeton Investment Funds – 
 Franklin Biotechnology Discovery Fund 

Franklin Advisers, Inc. 
 One Franklin Parkway 

San Mateo, CA 94403, USA 
 (“Franklin
Templeton”) 
 (Franklin Strategic and Franklin Templeton together “Franklin”) 

Clough Healthcare Master Fund, L.P. 
 c/o Clough Capital Partners
L.P. 
 One Post Office Square, 40th Floor 
 Boston, MA 02109,
USA 
 (“Clough Healthcare”) 

Clough Global Opportunities Fund 
 c/o Clough Capital Partners
L.P. 
 One Post Office Square, 40th Floor 
 Boston, MA 02109,
USA 
 (“Clough Opportunities”) 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 2

  

 Clough Global Equity Fund 

c/o Clough Capital Partners L.P. 
 One Post Office Square, 40th
Floor 
 Boston, MA 02109, USA 
 (“Clough
Equity”) 
 (Clough Healthcare, Clough Opportunities and Clough Equity together “Clough”) 

OrbiMed Partners II, LP 
 601 Lexington Avenue, 54th Floor 

New York, NY 10022 
 (“OrbiMed
II”) 
 OrbiMed Partners Master Fund Limited 
 601
Lexington Avenue, 54th Floor 
 New York, NY 10022 

(“OrbiMed Master”) 

(OrbiMed II and Orbimed Master together “OrbiMed”) 

New Leaf Growth Fund I, L.P. 
 New Leaf Venture Partners, L.L.C.

 7 Times Square, Suite 3502 
 New York, NY 10036 

(“NLV”) 
 Novo A/S 

Tuborg Havnevej 19 
 DK 2900 Hellerup 

(“Novo A/S”) 
 Vivo Capital Fund
VIII, L.P. 
 575 High Street, Suite 201 
 Palo Alto, CA 94301,
USA 
 (“Vivo Capital”) 
 Vivo
Capital Surplus Fund VIII, L.P. 
 575 High Street, Suite 201 

Palo Alto, CA 94301, USA 
 (“Vivo
Surplus”) 
 (Vivo Capital and Vivo Surplus together “Vivo”) 

an “Initial Holder”), 

and 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 3

  

 Crispr Therapeutics AG 

Aeschenvorstadt 36, 
 4051 Basel, Switzerland 

(“Company”) 
 (each
a “Party”, all together the “Parties”) 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 4

  

 CRISPR THERAPEUTICS AG 

REGISTRATION RIGHTS AGREEMENT 

RECITALS 

WHEREAS, the Initial Holders are holders of the Company’s Preferred Shares and/or Common Shares issued upon the conversion
thereof; and 
 WHEREAS, the Company and the Initial Holders hereby agree that this Registration Rights Agreement shall govern the
rights of the Initial Holders to cause the Company to register certain Common Shares issued or issuable to the Initial Holders and shall govern certain other matters as set forth in this Registration Rights Agreement; 

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein and other good and valuable consideration, the
receipt and sufficiency of which is acknowledged by the Parties, the Parties, intending to be legally bound, do hereby agree as follows: 

This Registration Rights Agreement shall become automatically effective (such date, the “Effective Date”), without the action
of any Party hereto, upon the termination of the Shareholders’ Agreement, dated April 13, 2015, by and among the Company and the Shareholders (as amended, the “Shareholders’ Agreement”) pursuant to Section 23.2 thereof.

 SECTION 1 

DEFINITIONS 
 1.1
Certain Definitions 
 As used in this Registration Rights Agreement, the following terms shall have the meanings set forth below: 

(a) “Articles of Association” shall mean the Articles of Association of the Company as amended from time to time. 

(b) “Commission” shall mean the United States Securities and Exchange Commission or any other federal agency in the
United States at the time administering the Securities Act. 
 (c) “Common Shares” shall mean the common shares of
the Company with a nominal value of CHF 0.10 each per Common Share, and having no preference rights. 
 (d)
“Control” shall mean, with respect to any Person, (a) the possession, directly or indirectly, of the power to direct or cause to direct the board of directors or the management of such Person through the ownership of voting
shares or other rights, by contract or otherwise, or (b) the ownership, directly or indirectly, of a majority of the voting shares or equity interests in such Person. 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 5

  

 (e) “Exchange Act” shall mean the United States Securities Exchange
Act of 1934, as amended, or any similar successor federal statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. 

(f) “Holder” shall mean any Shareholder who holds Registrable Securities and any holder of Registrable Securities to
whom the registration rights conferred by this Registration Rights Agreement have been duly and validly transferred in accordance with Section 2.12 of this Registration Rights Agreement. 

(g) “Indemnified Party” shall have the meaning set forth in Section 2.6(c). 

(h) “Indemnifying Party” shall have the meaning set forth in Section 2.6(c). 

(i) “Initiating Holders” shall mean any Holder or Holders who in the aggregate hold not less than 66 2/3% of the
outstanding Registrable Securities. 
 (j) “IPO” shall mean the closing of a firmly underwritten initial public
offering of the Common Shares that is pursuant to a registration statement under the Securities Act. 
 (k) “Preferred
Shares” shall mean the Series A-1, Series A-2 and Series A-3 Preferred Shares and Series B Preferred Shares. 
 (l)
“Registrable Securities” shall mean (i) Common Shares issued or issuable pursuant to the conversion of the Shares and (ii) any Common Shares issued as a dividend or other distribution with respect to or in exchange for
or in replacement of the shares referenced in (i) above; provided, however, that Registrable Securities shall not include any shares of Common Shares described in clause (i) or (ii) above which have been: (x) acquired pursuant to
Special Mandatory Conversion set forth in Section 19.2 of the Shareholders’ Agreement, (y) previously registered or which have been sold to the public either pursuant to a registration statement or Rule 144, or (z) which have been sold in
a private transaction in which the transferor’s rights under this Registration Rights Agreement are not validly assigned in accordance with this Registration Rights Agreement. 

(m) The terms “register,” “registered” and “registration” shall refer
to a registration effected by preparing and filing a registration statement in compliance with the Securities Act and applicable rules and regulations thereunder, and the declaration or ordering of the effectiveness of such registration statement.

 (n) “Registration Expenses” shall mean all expenses incurred in effecting any registration pursuant to this
Registration Rights Agreement, including, without limitation, all registration, qualification, and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, fees and disbursements of one special counsel for all
Holders (in an amount not to exceed $35,000 for such special counsel), blue sky fees and expenses, and expenses of any regular or special audits incident to or required by any such registration, but shall not include Selling Expenses, fees and
disbursements of any other counsel for the Holders and the compensation of regular employees of the Company, which shall be paid in any event by the Company. 

(o) “Restricted Securities” shall mean any Registrable Securities required to bear the first legend set forth in
Section 2.8(a). 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 6

  

 (p) “Rule 144” shall mean
Rule 144 as promulgated by the Commission under the Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission. 

(q) “Rule 145” shall mean Rule 145 as promulgated by the Commission under the
Securities Act, as such Rule may be amended from time to time, or any similar successor rule that may be promulgated by the Commission 

(r) “Securities Act” shall mean the United States Securities Act of 1933, as amended, or any similar successor federal
statute and the rules and regulations thereunder, all as the same shall be in effect from time to time. 
 (s) “Selling
Expenses” shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the sale of Registrable Securities and fees and disbursements of counsel for any Holder. 

(t) “Series A-1 Preferred Shares” shall mean the Series A-1 preferred shares (Vorzugsaktien der Serie A-1 / actions
privilégiées série A-1) with a nominal value of CHF 0.10 each per Series A-1 Preferred Share, and having the preference rights set forth in the Articles of Association. 

(u) “Series A-2 Preferred Shares” shall mean the Series A-2 preferred shares (Vorzugsaktien der Serie A-2 / actions
privilégiées série A-2) with a nominal value of CHF 0.10 each per Series A-2 Preferred Share, and having the preference rights set forth in the Articles of Association. 

(v) “Series A-3 Preferred Shares” shall mean the Series A-3 preferred shares (Vorzugsaktien der Serie A-3 / actions
privilégiées série A-3) with a nominal value of CHF 0.10 each per Series A-3 Preferred Share, and having the preference rights set forth in the Articles of Association. 

(w) “Series B Preferred Shares” shall mean the Series B preferred shares (Vorzugsaktien der Serie B / actions
privilégiées série B) with a nominal value of CHF 0.10 each per Series B Preferred Share, and having the preference rights set forth in the Articles of Association. 

(x) “Shares” shall mean the Preferred Shares. 

(y) “Shareholder” shall mean any holder of Shares who is a party to this Registration Rights Agreement. 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 7

  

 SECTION 2 

REGISTRATION RIGHTS 

2.1 Requested Registration 

(a) Request for Registration. Subject to the conditions set forth in this Section 2.1, if the Company shall receive from
Initiating Holders a written request signed by such Initiating Holders that the Company effect any registration with respect to all or a part of the Registrable Securities (such request shall state the number of shares of Registrable Securities to
be disposed of and the intended methods of disposition of such shares by such Initiating Holders), the Company will: 
 (i) promptly give
written notice of the proposed registration to all other Holders; and 
 (ii) as soon as practicable, file and use its commercially
reasonable efforts to effect such registration (including, without limitation, filing post-effective amendments, appropriate qualifications under applicable blue sky or other state securities laws, and appropriate compliance with the Securities Act)
and to permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders joining in such
request as are specified in a written request received by the Company within twenty (20) days after such written notice from the Company is mailed or delivered. 

(b) Limitations on Requested Registration. The Company shall not be obligated to effect, or to take any action to effect, any
such registration pursuant to this Section 2.1: 
 (i) Prior to the earlier of (A) the three (3) year anniversary of the date of
the Investment Agreement, dated June 10, 2016, by and among the Company and the other parties thereto (the “Investment Agreement”) or (B) one hundred eighty (180) days following the effective date of the registration statement
filed by the Company for an IPO (or the subsequent date on which all market stand-off agreements applicable to the offering have terminated); 

(ii) If the Initiating Holders, together with the holders of any other securities of the Company entitled to inclusion in such registration
statement, propose to sell Registrable Securities and such other securities (if any) the aggregate proceeds of which (after deduction for underwriter’s discounts and expenses related to the issuance) are less than $10,000,000; 

(iii) In any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting
such registration, qualification, or compliance, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act; 

(iv) After the Company has initiated two such registrations pursuant to this Section 2.1; 

(v) During the period starting with the date sixty (60) days prior to the Company’s good faith estimate of the date of filing of, and
ending on a date one hundred eighty (180) days after the effective date of, a Company-initiated registration (or ending on the subsequent date on which all market stand-off agreements applicable to the offering have terminated); provided that
the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or 

(vi) If the Initiating Holders propose to dispose of shares of Registrable Securities that may be registered on Form S-3 pursuant to a request made under Section 2.3; 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 8

  

 (vii) If the Initiating Holders do not request that such offering be firmly underwritten by
underwriters selected by the Initiating Holders (subject to the consent of the Company); or 
 (viii) If the Company and the Initiating
Holders are unable to obtain the commitment of the underwriter described in clause (b)(vii) above to firmly underwrite the offer. 
 (c)
Deferral. If (i) in the good faith judgment of the Board of Directors of the Company (the “Board”), the filing of a registration statement covering the Registrable Securities would be detrimental to the Company
and the Board concludes, as a result, that it is in the best interests of the Company to defer the taking of any action with respect to the filing of such registration statement at such time, and (ii) the Company furnishes to Holders requesting
a registration pursuant to Section 2.1 a certificate signed by the President of the Company stating that in the good faith judgment of the Board, it would be detrimental to the Company for such registration statement to be filed in the near future
and that it is, therefore, in the best interests of the Company to defer taking action with respect to the filing of such registration statement, then (in addition to the limitations set forth in Section 2.1(b)(v) above) the Company shall have
the right to defer such filing for a period of not more than one hundred eighty (180) days after receipt of the request of the Initiating Holders, and, provided further, that the Company shall not defer its obligation in this manner more than twice
in any twelve-month period. 
 (d) Underwriting. If the Initiating Holders intend to distribute the Registrable Securities
covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to this Section 2.1 and the Company shall include such information in the written notice given pursuant to
Section 2.1(a)(i). In such event, the right of any Holder to include all or any portion of its Registrable Securities in such registration pursuant to this Section 2.1 shall be conditioned upon such Holder’s participation in such
underwriting and the inclusion of such Holder’s Registrable Securities to the extent provided herein. If the Company shall request inclusion in any registration pursuant to Section 2.1 of securities being sold for its own account, or if
other persons shall request inclusion in any registration pursuant to Section 2.1, the Initiating Holders shall, on behalf of all Holders, offer to include such securities in the underwriting and such offer shall be conditioned upon the
participation of the Company or such other persons in such underwriting and the inclusion of the Company’s and such person’s other securities of the Company and their acceptance of the further applicable provisions of this Section 2
(including Section 2.10). The Company shall (together with all Holders proposing to distribute their securities through such underwriting) enter into an underwriting agreement in customary form with the representative of the underwriter or
underwriters selected for such underwriting by a majority in interest of the Initiating Holders subject to the consent of the Company. 

Notwithstanding any other provision of this Section 2.1, if the underwriters advise the Initiating Holders in writing that marketing
factors require a limitation on the number of shares to be underwritten, the number of Registrable Securities that may be so included shall be allocated among all Holders requesting to include Registrable Securities in such registration statement
based on the pro rata percentage of Registrable Securities held by such Holders, assuming conversion. 
 If a person who has
requested inclusion in such registration as provided above does not agree to the terms of any such underwriting, such person shall be excluded therefrom by written notice from the Company, the underwriter or the Initiating Holders. The securities so
excluded shall also be withdrawn from registration. Any Registrable Securities or other securities excluded or withdrawn from such underwriting shall also be withdrawn from such registration. If shares are so withdrawn from the

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 9

  

 
registration and if the number of shares to be included in such registration was previously reduced as a result of marketing factors pursuant to this Section 2.1(d), then the Company shall
then offer to all Holders who have retained rights to include securities in the registration the right to include additional Registrable Securities in the registration in an aggregate amount equal to the number of shares so withdrawn, with such
shares to be allocated among such Holders requesting additional inclusion, as set forth above. 
 2.2 Company Registration 

(a) Company Registration. If the Company shall determine to register any of its securities under the Securities Act in
connection with a public offering of securities for cash either for its own account or the account of a security holder or holders, other than a registration pursuant to Section 2.1 or 2.3, a registration relating solely to employee benefit
plans, a registration relating to the offer and sale of debt securities, a registration relating to a corporate reorganization or other Rule 145 transaction, or a registration on any registration form that does not permit secondary sales, the
Company will: 
 (i) promptly give written notice of the proposed registration to all Holders; and 

(ii) use its commercially reasonable efforts to include in such registration (and any related qualification under blue sky laws or other
compliance), except as set forth in Section 2.2(b) below, and in any underwriting involved therein, all of such Registrable Securities as are specified in a written request or requests made by any Holder or Holders received by the Company
within ten (10) days after such written notice from the Company is mailed or delivered. Such written request may specify all or a part of a Holder’s Registrable Securities. 

(b) Underwriting. If the registration of which the Company gives notice is for a registered public offering involving an
underwriting, the Company shall so advise the Holders as a part of the written notice given pursuant to Section 2.2(a)(i). In such event, the right of any Holder to registration pursuant to this Section 2.2 shall be conditioned upon such
Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall
(together with the Company and other holders of securities of the Company with registration rights to participate therein distributing their securities through such underwriting) enter into an underwriting agreement in customary form with the
representative of the underwriter or underwriters selected by the Company. 
 Notwithstanding any other provision of this Section 2.2,
if the underwriters advise the Company in writing that marketing factors require a limitation on the number of shares to be underwritten, the underwriters may (subject to the limitations set forth below) exclude all Registrable Securities from, or
limit the number of Registrable Securities to be included in, the registration and underwriting. The Company shall so advise all holders of securities requesting registration, and the number of shares of securities that are entitled to be included
in the registration and underwriting shall be allocated, as follows: (i) first, to the Company for securities being sold for its own account, (ii) second, to the Holders requesting to include Registrable Securities in such registration statement
based on the pro rata percentage of Registrable Securities held by such Holders, assuming conversion and (iii) third, to any other stockholder requesting to include shares held by such stockholder in such registration statement based on the
pro rata percentage of shares held by such stockholders, assuming conversion. 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 10

  

 
Notwithstanding the foregoing, in no event shall the number of Registrable Securities included in the offering be reduced below twenty percent (20%) of the total number of securities included in
such offering, unless such offering is the IPO, in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder’s securities are included in such offering. 

If a person who has requested inclusion in such registration as provided above does not agree to the terms of any such underwriting, such
person shall also be excluded therefrom by written notice from the Company or the underwriter. The Registrable Securities or other securities so excluded shall also be withdrawn from such registration. Any Registrable Securities or other securities
excluded or withdrawn from such underwriting shall be withdrawn from such registration. If shares are so withdrawn from the registration and if the number of shares of Registrable Securities to be included in such registration was previously reduced
as a result of marketing factors pursuant to Section 2.2(b), the Company shall then offer to all persons who have retained the right to include securities in the registration the right to include additional securities in the registration in an
aggregate amount equal to the number of shares so withdrawn, with such shares to be allocated among the persons requesting additional inclusion, in the manner set forth above. 

(c) Right to Terminate Registration. The Company shall have the right to terminate or withdraw any registration initiated by it
under this Section 2.2 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. 

2.3 Registration on Form S-3 

(a) Request for Form S-3 Registration. After its IPO, the
Company shall use its commercially reasonable efforts to qualify for registration on Form S-3 or any comparable or successor form or forms. After the Company has qualified for the use of Form S-3, in addition to the rights contained in the foregoing
provisions of this Section 2 and subject to the conditions set forth in this Section 2.3, if the Company shall receive from a Holder or Holders of Registrable Securities a written request that the Company effect any registration on Form S-3 or any similar short form registration statement with respect to all or part of the Registrable Securities (such request shall state the number of shares of Registrable Securities to be disposed of and the
intended methods of disposition of such shares by such Holder or Holders), the Company will take all such action with respect to such Registrable Securities as required by Section 2.1(a)(i) and 2.1(a)(ii). 

(b) Limitations on Form S-3 Registration. The Company shall
not be obligated to effect, or take any action to effect, any such registration pursuant to this Section 2.3: 
 (i) In the
circumstances described in either Sections 2.1(b)(i), 2.1(b)(iii) or 2.1(b)(v); 
 (ii) If the Holders, together with the holders of
any other securities of the Company entitled to inclusion in such registration, propose to sell Registrable Securities and such other securities (if any) on Form S-3 at an aggregate price to the public of less than $2,000,000; or 

(iii) If, in a given twelve-month period, the Company has effected one (1) such registration in such period. 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 11

  

 (c) Deferral. The provisions of Section 2.1(c) shall apply to any
registration pursuant to this Section 2.3. 
 (d) Underwriting. If the Holders of Registrable Securities requesting
registration under this Section 2.3 intend to distribute the Registrable Securities covered by their request by means of an underwriting, the provisions of Section 2.1(d) shall apply to such registration. Notwithstanding anything contained
herein to the contrary, registrations effected pursuant to this Section 2.3 shall not be counted as requests for registration or registrations effected pursuant to Section 2.1. 

2.4 Expenses of Registration 

All Registration Expenses incurred in connection with registrations pursuant to Sections 2.1, 2.2 and 2.3 shall be borne by the Company;
provided, however, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Sections 2.1 and 2.3 if the registration request is subsequently withdrawn at the request of the Holders
of a majority of the Registrable Securities to be registered or because a sufficient number of Holders shall have withdrawn so that the minimum offering conditions set forth in Sections 2.1 and 2.3 are no longer satisfied (in which case all
participating Holders shall bear such expenses pro rata among each other based on the number of Registrable Securities requested to be so registered), unless the Holders of a majority of the Registrable Securities agree to forfeit their right
to a demand registration pursuant to Section 2.1. All Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the holders of securities included in such registration pro rata among each other on the
basis of the number of Registrable Securities so registered. 
 2.5 Registration Procedures 

In the case of each registration effected by the Company pursuant to Section 2, the Company will keep each Holder advised in writing as
to the initiation of each registration and as to the completion thereof. At its expense, the Company will use its commercially reasonable efforts to: 

(a) Keep such registration effective for a period ending on the earlier of the date which is sixty (60) days from the effective date of the
registration statement or such time as the Holder or Holders have completed the distribution described in the registration statement relating thereto; 

(b) Prepare and file with the Commission such amendments and supplements to such registration statement and the prospectus used in connection
with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration statement for the period set forth in subsection (a) above;

 (c) Furnish such number of prospectuses, including any preliminary prospectuses, and other documents incident thereto, including any
amendment of or supplement to the prospectus, as a Holder from time to time may reasonably request; 
 (d) Use its commercially reasonable
efforts to register and qualify the securities covered by such registration statement under such other securities or blue sky laws of such jurisdiction as shall be reasonably requested by the Holders; provided, that the Company shall not be
required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or jurisdictions; 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 12

  

 (e) Notify each seller of Registrable Securities covered by such registration statement at
any time when a prospectus relating thereto is required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue
statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing, and following such notification
promptly prepare and furnish to such seller a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include
an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in light of the circumstances then existing; 

(f) Provide a transfer agent and registrar for all Registrable Securities registered pursuant to such registration statement and a CUSIP
number for all such Registrable Securities, in each case not later than the effective date of such registration; 
 (g) Cause all such
Registrable Securities registered pursuant hereunder to be listed on each securities exchange on which similar securities issued by the Company are then listed; and 

(h) In connection with any underwritten offering pursuant to a registration statement filed pursuant to Section 2.1, enter into an
underwriting agreement in form reasonably necessary to effect the offer and sale of Common Shares, provided such underwriting agreement contains reasonable and customary provisions, and provided further, that each Holder participating in such
underwriting shall also enter into and perform its obligations under such an agreement. 
 2.6 Indemnification 

(a) To the extent permitted by law, the Company will indemnify and hold harmless each Holder, each of its officers, directors and partners,
legal counsel, accountants and investment advisers and each person controlling such Holder within the meaning of Section 15 of the Securities Act, with respect to which registration, qualification or compliance has been effected pursuant to
this Section 2, and each underwriter, if any, for such Holder, and each person who controls within the meaning of Section 15 of the Securities Act any underwriter, against all expenses, claims, losses, damages and liabilities (or actions,
proceedings or settlements in respect thereof) arising out of or based on: (i) any untrue statement (or alleged untrue statement) of a material fact contained or incorporated by reference in any registration statement, any prospectus included
in the registration statement, any issuer free writing prospectus (as defined in Rule 433 of the Securities Act), any issuer information (as defined in Rule 433 of the Securities Act) filed or required to be filed pursuant to
Rule 433(d) under the Securities Act or any other document incident to any such registration, qualification or compliance prepared by or on behalf of the Company or used or referred to by the Company, (ii) any omission (or alleged
omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation (or alleged violation) by the Company of the Securities Act, any state securities laws
or any rule or regulation thereunder applicable to the Company and relating to action or inaction required of the Company in connection with any offering covered by such registration, qualification or compliance, and the Company will reimburse each
such Holder, each of its officers, directors, partners, legal counsel, accountants and investment advisers and each person controlling such Holder, each such underwriter and each person who controls any such underwriter, for any legal and any other
expenses reasonably incurred in connection with investigating and defending or settling any such 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 13

  

 
claim, loss, damage, liability or action; provided that the Company will not be liable in any such case to the extent that any such claim, loss, damage, liability, or action arises out of
or is based on any untrue statement or omission based upon written information furnished to the Company by such Holder, any of such Holder’s officers, directors, partners, legal counsel, accountants or investment advisers, any person
controlling such Holder, such underwriter or any person who controls any such underwriter, and stated to be specifically for use therein; and provided, further that, the indemnity agreement contained in this Section 2.6(a) shall
not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not be unreasonably withheld). 

(b) To the extent permitted by law, each Holder will, if Registrable Securities held by such Holder are included in the securities as to which
such registration, qualification or compliance is being effected, indemnify and hold harmless the Company, each of its directors, officers, partners, legal counsel and accountants and each underwriter, if any, of the Company’s securities
covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of Section 15 of the Securities Act, each other such Holder, and each of their officers, directors and partners, and each
person controlling each other such Holder, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on: (i) any untrue statement (or alleged untrue statement) of a material fact contained or
incorporated by reference in any prospectus, offering circular or other document (including any related registration statement, notification, or the like) incident to any such registration, qualification or compliance, (ii) any omission (or
alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or (iii) any violation (or alleged violation) by the Holder of the Securities Act, any state securities
laws or any rule or regulation thereunder applicable to the Holder and relating to action or inaction required of the Holder in connection with any offering covered by such registration, qualification or compliance, and will reimburse the Company
and such Holders, directors, officers, partners, legal counsel and accountants, persons, underwriters, or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such claim, loss,
damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or
other document in reliance upon and in conformity with written information furnished to the Company by or on behalf of such Holder expressly for use in connection with such registration, qualification or compliance; provided, however,
that the obligations of such Holder hereunder shall not apply to amounts paid in settlement of any such claims, losses, damages or liabilities (or actions in respect thereof) if such settlement is effected without the consent of such Holder (which
consent shall not be unreasonably withheld); and provided that in no event shall any indemnity under this Section 2.6 exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in
the case of fraud or willful misconduct by such Holder. 
 (c) Each party entitled to indemnification under this Section 2.6 (the
“Indemnified Party”) shall give notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has
actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of such claim or any litigation resulting therefrom; provided that counsel for the Indemnifying Party, who shall
conduct the defense of such claim or any litigation resulting therefrom, shall be approved by the Indemnified Party (whose approval shall not be unreasonably withheld), and the Indemnified Party may participate in such defense at such party’s
expense; and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the Indemnifying Party of its obligations under this Section 2.6, to the

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 14

  

 
extent such failure is not prejudicial. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party, consent to entry of any
judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release from all liability in respect to such claim or litigation. Each Indemnified
Party shall furnish such information regarding itself or the claim in question as an Indemnifying Party may reasonably request in writing and as shall be reasonably required in connection with defense of such claim and litigation resulting
therefrom. 
 (d) If the indemnification provided for in this Section 2.6 is held by a court of competent jurisdiction to be
unavailable to an Indemnified Party with respect to any loss, liability, claim, damage, or expense referred to herein, then the Indemnifying Party, in lieu of indemnifying such Indemnified Party hereunder, shall contribute to the amount paid or
payable by such Indemnified Party as a result of such loss, liability, claim, damage, or expense in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party on the one hand and of the Indemnified Party on the other
in connection with the statements or omissions that resulted in such loss, liability, claim, damage, or expense as well as any other relevant equitable considerations. The relative fault of the Indemnifying Party and of the Indemnified Party shall
be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the Indemnifying Party or by the Indemnified Party and
the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission. No person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the
Securities Act) will be entitled to contribution from any person or entity who was not guilty of such fraudulent misrepresentation. Notwithstanding the foregoing, in no event shall a Holder’s liability pursuant to this Section 2.6(d), when
combined with amounts paid or payable by such Holder pursuant to Section 2.6(b), exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by
such Holder. 
 (e) Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the
underwriting agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall control. 

2.7 Information by Holder 

Each Holder of Registrable Securities shall furnish to the Company such information regarding such Holder and the distribution proposed by
such Holder as the Company may reasonably request in writing and as shall be reasonably required in connection with any registration, qualification, or compliance referred to in this Section 2. 

2.8 Restrictions on Transfer 

(a) Each certificate representing Registrable Securities shall (unless otherwise permitted by the provisions of this Registration Rights
Agreement) be stamped or otherwise imprinted with a legend substantially similar to the following (in addition to any legend required under applicable state securities laws): 

THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO (1) RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 15

  

 
A LOCK-UP PERIOD IN THE EVENT OF A PUBLIC OFFERING, AS SET FORTH IN A REGISTRATION RIGHTS AGREEMENT AMONG THE COMPANY AND THE ORIGINAL HOLDERS OF THESE SHARES, COPIES OF WHICH MAY BE OBTAINED AT
THE PRINCIPAL OFFICE OF THE COMPANY. 
 The Holders consent to the Company making a notation on its records and giving instructions to any
transfer agent of the Restricted Securities in order to implement the restrictions on transfer established in this Section 2.8. 
 (b)
Each Holder, by acceptance of ownership of Restricted Securities, agrees to comply in all respects with the provisions of this Section 2.8. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect
a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the
manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably requested by the Company, shall be accompanied at such Holder’s expense by either (i) a written opinion of legal counsel who shall, and
whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction may be effected without registration under the Securities Act; (ii) a “no action” letter from the
SEC to the effect that the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the staff of the SEC that action be taken with respect thereto; or (iii) any other evidence
reasonably satisfactory to counsel to the Company to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the Securities Act, whereupon the Holder of such Restricted
Securities shall be entitled to sell, pledge, or transfer such Restricted Securities in accordance with the terms of the notice given by the Holder to the Company, subject to any other restrictions or obligations arising pursuant to
Section 2.12 of this Registration Rights Agreement. The Company will not require such a legal opinion or “no action” letter (x) in any transaction in compliance with Rule 144; or (y) in any transaction in which such Holder
distributes Restricted Securities to a Permitted Transferee for no consideration; provided that each transferee agrees in writing to be subject to the terms of this Section 2.8. Each certificate, instrument, or book entry representing
the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to Rule 144, the appropriate restrictive legend set forth above, except that such certificate instrument, or book entry shall not
be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act. 

(c) “Permitted Transferee” means: 

(i) If the original transferor is a Shareholder being a corporate body (irrespective of its corporate form), any corporate body over which
Control is exerted by, or which has Control over, or which is under the same Control as the original transferor; 
 (ii) (x) a parent,
subsidiary or other affiliate of the Shareholder, if the Shareholder is a corporation, (y) any of the Shareholder’s partners,, members or other equity owners, or retired partners, retired members or other equity owners, or to the estate of any
of the Shareholder’s partners, members or other equity owners or retired partners, retired members or other equity owners, or (z) a venture capital fund or another investment fund or account that is controlled by or under common control with
one or more general partners or managing members of, or shares the same management company with, the Shareholder; and 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 16

  

 (iii) If the original transferor is an individual, (i) any member of his or her immediate
family (which shall be deemed to comprise parents, grandparents, children (whether legitimate or not), grandchildren, siblings and children and grandchildren of siblings); or (ii) any trustee from time to time of any trust of which all the
beneficiaries are members of his or her immediate family; or (iii) any corporate body which is under the original transferor’s or any of his or her Permitted Transferees’ Control. 

2.9 Rule 144 Reporting 

With a view to making available the benefits of certain rules and regulations of the Commission that may permit the sale of the Restricted
Securities to the public without registration, the Company agrees to use its commercially reasonable efforts to: 
 (a) Make and keep
adequate current public information with respect to the Company available in accordance with Rule 144 under the Securities Act, at all times from and after ninety (90) days following the effective date of the first registration under the
Securities Act filed by the Company for an offering of its securities to the general public; 
 (b) File with the Commission in a timely
manner all reports and other documents required of the Company under the Securities Act and the Exchange Act at any time after it has become subject to such reporting requirements; and 

(c) So long as a Holder owns any Restricted Securities, furnish to the Holder forthwith upon written request a written statement by the
Company as to its compliance with the reporting requirements of Rule 144 (at any time from and after ninety (90) days following the effective date of the first registration statement filed by the Company for an offering of its securities to the
general public), and of the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents so
filed as a Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such securities without registration. 

2.10 Market Stand-Off Agreement 

In connection with the Company’s initial public offering, each Holder shall execute a lock-up agreement in substantially the form
attached hereto as Annex A; provided that all officers, directors, and stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Shares (after giving effect to conversion into Common Shares of all
outstanding Preferred Shares) are subject to the same restrictions. Such form cannot be amended without the consent of each Holder that alone or together with its Affiliates initially acquired at least 100,000 Preferred Shares. 

2.11 Delay of Registration 

No Holder shall have any right to take any action to restrain, enjoin, or otherwise delay any registration as the result of any controversy
that might arise with respect to the interpretation or implementation of this Section 2. 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 17

  

 2.12 Transfer or Assignment of Registration Rights 

The rights to cause the Company to register securities granted to a Holder by the Company under this Section 2 may be transferred or
assigned by a Holder only to a transferee or assignee that is a (i) Permitted Transferee; or (ii) after such transfer, holds alone or together with its Affiliates not less than 100,000 shares of Registrable Securities (as presently constituted and
subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like); provided that (i) such transfer or assignment of Registrable Securities is effected in accordance with the terms of this
Registration Rights Agreement, and applicable securities laws, (ii) the Company is given written notice prior to said transfer or assignment, stating the name and address of the transferee or assignee and identifying the securities with respect
to which such registration rights are intended to be transferred or assigned and (iii) the transferee or assignee agrees in a written instrument to be bound by and subject to the terms, conditions and obligations of this Registration Rights
Agreement. 
 2.13 Limitations on Subsequent Registration Rights 

From and after the date of the Investment Agreement, the Company shall not, without the prior written consent of Holders holding at least a 66
2/3% of the Registrable Securities (excluding any of such shares held by any Holders whose rights to request registration or inclusion in any registration pursuant to this Section 2 have terminated in accordance with Section 2.14), enter
into any agreement with any holder or prospective holder of any securities of the Company giving such holder or prospective holder any registration rights the terms of which are senior to the registration rights granted to the Holders hereunder.

 2.14 Termination of Registration Rights 

The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Sections 2.1, 2.2
or 2.3 shall terminate on the earlier of: (i) such date, on or after the closing of the Company’s first registered public offering of Common Shares, on which all shares of Registrable Securities held or entitled to be held upon conversion
by such Holder may immediately be sold under Rule 144 during any ninety (90) day period, and (ii) five (5) years after the closing of the IPO. 

2.15 Governing Law and Place of Jurisdiction 

This Registration Rights Agreement and all disputes including those concerning any statute of limitations, set-off claims, tort claims and
interest claims, shall be governed by the laws of Switzerland including all matters of construction and validity, without giving effect to its conflict of laws provisions. The ordinary courts at the place of the registered offices of the Company
shall have exclusive jurisdiction with regard to any dispute arising between the Parties out or in connection with this Registration Rights Agreement (including a dispute regarding the construction and validity thereof). 

2.16 Notices 
 Any notice
with legal effect given under the provisions of this Registration Rights Agreement by any of the Parties hereto shall be given in English and by registered mail, courier or telefax and shall be sent to the addresses herein above mentioned with an
additional copy to the Chairman of the Board. Any change of the above addresses shall be communicated to the other Party pursuant to this Section 2.16 to be validly notified. Any information may be delivered by e-mail. Unless notice is given by
registered mail or against return receipt, the notifying Party bears the burden of proof that the notice was timely dispatched or received by the other Party or Parties, respectively. 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 18

  

 2.17 Modifications 

Subject to Section 2.18, any modification and amendment of this Registration Rights Agreement shall be in writing and signed by shareholders
representing the majority the Initial Holders. If this Registration Rights Agreement requires a modification or an amendment due to the exit of one or several Shareholders, the Parties undertake to enter into respective bona fide negotiations with
each other. 
 2.18 Severability 

In the event that any of the terms or provisions of this Registration Rights Agreement is determined to be invalid or nil/void or if any
provision or term of this Registration Rights Agreement shall become invalid or nil/void at any time hereafter, then all other provisions of this Registration Rights Agreement shall remain valid and effective in accordance with their terms. The
Parties agree that a provision which shall be determined to be or which shall become invalid or nil/void shall be substituted by another suitable provision which shall maintain the economic purposes of this Registration Rights Agreement. The same
shall apply in the case of a contractual gap. 
 2.19 Entire Agreement 

This Registration Rights Agreement together with all documents referred to herein constitute the entire agreement between the Parties with
respect to the subject matter of this Registration Rights Agreement and supersede all other prior written and oral agreements of the Parties relating thereto, including Annex 19.8 of the Shareholder’s Agreement from and after the Effective
Date. 
 2.20 General Rule 

This Registration Rights Agreement shall apply to all present and future Shares of the Company which are currently owned by the Shareholders
or which will be acquired at any time during the term of this Agreement by the Shareholders or future shareholders of the Company. This Registration Rights Agreement shall also apply to shares received in the process of a de-merger of the
Company or as dividend in kind from the Company. 
 2.21 Counterparts 

This Registration Rights Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or
other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.  

2.22 Titles and Subtitles 

The titles and subtitles used in this Registration Rights Agreement are for convenience only and are not to be considered in construing or
interpreting this Registration Rights Agreement. 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 19

  

 2.23    Delays or Omissions 

No delay or omission to exercise any right, power, or remedy accruing to any party under this Registration Rights Agreement, upon any breach
or default of any other party under this Registration Rights Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or
default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this
Registration Rights Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative. 
 IN WITNESS
WHEREOF the Parties have caused this Agreement to be duly executed as of the date first written above. 
 [Signature page following] 

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 20

  

 Signatures 
  

									
	Place/Date:	 	 June 10, 2016
	 		 	Place/Date:	 	 San Mateo, CA 6/10/16

  

									
	Hadley Harbor Master Investors (Cayman) L.P.	 		 	Franklin Strategic Series – Franklin Biotechnology Discovery Fund
			
	By: Wellington Management Company LLP, its investment adviser	 		 	By: Franklin Advisers, Inc., its investment manager
					
	By:	 	/s/ Emily Babalas	 		 	By:	 	/s/ Evan McCulloch
					
	Name:	 	Emily Babalas	 		 	Name:	 	Evan McCulloch
					
	Title:	 	Managing Director and Counsel	 		 	Title:	 	Senior Vice President

  

									
	Place/Date:	 	 San Mateo, CA 6/10/16
	 		 	Place/Date:	 	 6/10/2016

  

									
	Franklin Templeton Investment Funds – Franklin Biotechnology Discovery Fund	 		 	Clough Healthcare Master Fund, L.P.
			
	By: Franklin Advisers, Inc., its investment manager	 		 	By: Clough Capital Partners L.P., its investment manager
					
	By:	 	/s/ Evan McCulloch	 		 	By:	 	/s/ Daniel J. Gillis
					
	Name:	 	Evan McCulloch	 		 	Name:	 	Daniel J. Gillis
					
	Title:	 	Senior Vice President	 		 	Title:	 	Chief Compliance Officer

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 21

  

									
	Place/Date:	 	 6/10/2016
	 		 	Place/Date:	 	 6/10/2016

  

									
	Clough Global Opportunities Fund	 		 	Clough Global Equity Fund
			
	By: Clough Capital Partners L.P., its investment adviser	 		 	By: Clough Capital Partners L.P., its investment adviser
					
	By:	 	/s/ Daniel J. Gillis	 		 	By:	 	/s/ Daniel J. Gillis
					
	Name:	 	Daniel J. Gillis	 		 	Name:	 	Daniel J. Gillis
					
	Title:	 	Chief Compliance Officer	 		 	Title:	 	Chief Compliance Officer

  

									
	Place/Date:	 	 NY, NY 6/10/16
	 		 	Place/Date:	 	 NY, NY 6/10/16

  

									
	OrbiMed Partners II, L.P.	 		 	OrbiMed Partners Master Fund Limited
			
	By: OrbiMed Advisors LLC, its General Partner	 		 	By: OrbiMed Capital LLC, solely in its capacity as Investment Advisor
					
	By:	 	/s/ Geoff Hsu	 		 	By:	 	/s/ Geoff Hsu
					
	Name:	 	Geoff Hsu	 		 	Name:	 	Geoff Hsu
					
	Title:	 	Member	 		 	Title:	 	Member

  

									
	Place/Date:	 	  
	 		 	Place/Date:	 	 Hellerup 6/13/16

  

									
	New Leaf Growth Fund I, L.P.	 		 	Novo A/S
				
	By: New Leaf Growth Associates I, L.P.	 		 		 	
				
	Its: General Partner	 		 		 	
				
	By: New Leaf Venture Management III, L.L.C.	 		 		 	
				
	Its: General Partner	 		 		 	
					
	By:	 	/s/ Craig L. Slutzkin	 		 	By:	 	/s/ Thomas Dyrberg
					
	Name:	 	Craig L. Slutzkin	 		 	Name:	 	Thomas Dyrberg
					
	Title:	 	Chief Financial Officer	 		 	Title:	 	Managing Partner, Novo A/S

			
	Registration Rights Agreement re Crispr Therapeutics AG	  	
 22

  

									
	Place/Date:	 	  
	 		 	Place/Date:	 	  

  

									
	Vivo Capital Fund VIII, L.P.	 		 	Vivo Capital Surplus Fund VIII, L.P.
			
	By: Vivo Capital VIII, LLC	 		 	By: Vivo Capital VIII, LLC
			
	Its: General Partner	 		 	Its: General Partner
					
	By:	 	/s/ Chen Yu	 		 	By:	 	/s/ Chen Yu
					
	Name:	 	Chen Yu	 		 	Name:	 	Chen Yu
					
	Title:	 	Managing Member	 		 	Title:	 	Managing Member

  

											
	Place/Date:	 	 June 10, 2016
	 		 		 		 	

  

							
	Crispr Therapeutics AG	 		 	
				
	By:	 	/s/ Rodger Novak	 		 	
				
	Name:	 	Rodger Novak	 		 	
				
	Title:	 	CEO	 		 	

 Annex A 

Lock-up Agreement 

 [letterhead of officer, director or major shareholder of 

                
issuer] 
 CRISPR Therapeutics AG 

Public Offering of Common Shares 

June    , 2016 
 Citigroup
Global Markets Inc. 
 Piper Jaffray & Co. 

As Representatives of the several Underwriters, 

c/o Citigroup Global Markets Inc. 
 388 Greenwich Street 

New York, New York 10013 
 Ladies and Gentlemen: 

This letter is being delivered to you in connection with the proposed underwriting agreement (the “Underwriting Agreement”),
among CRISPR Therapeutics AG, a stock corporation (Aktiengesellschaft) incorporated under the laws of Switzerland (the “Issuer”), and each of you as representatives of a group of underwriters named therein (the
“Underwriters”), relating to an underwritten public offering of common shares, nominal value CHF 0.10 per share (the “Common Shares”), of the Issuer (the “Offering”). 

In order to induce you and the other Underwriters to enter into the Underwriting Agreement, the undersigned will not, without the prior
written consent of Citigroup Global Markets Inc. and Piper Jaffray & Co. (together, the “Representatives”), offer, sell, contract to sell, pledge or otherwise dispose of, (or enter into any transaction which is designed to, or
might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the undersigned or any affiliate of the undersigned or any person in privity with the
undersigned or any affiliate of the undersigned), directly or indirectly, including the filing (or participation in the filing) of a registration statement with the Securities and Exchange Commission (the “SEC”) in respect of, or
establish or increase a put equivalent position or liquidate or decrease a call equivalent position within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and
regulations of the SEC promulgated thereunder with respect to, any shares of capital stock of the Issuer or any securities convertible into, or exercisable or exchangeable for such capital stock, or publicly announce an intention to effect any such
transaction, for a period commencing on the date hereof and continuing through 180 days after the date of the Underwriting Agreement (the “Lockup Period”), other than: 

(i) sales of Common Shares by the undersigned to the Underwriters pursuant to the Underwriting Agreement; 

  
 2 

 (ii) transactions relating to Common Shares or other securities convertible or exercisable into
Common Shares purchased in the Offering or acquired in open market transactions after the completion of the Offering; 
 (iii) transfers of
shares of capital stock of the Issuer or any securities convertible into, or exercisable or exchangeable for, such capital stock as a bona fide gift; 

(iv) exercise of options or warrants to purchase Common Shares or the receipt of Common Shares upon the vesting of restricted Common Share
awards and any related transfer of Common Shares to the Issuer in connection therewith (x) deemed to occur upon the “cashless” or “net” exercise of such options or warrants or (y) for the purpose of paying the exercise price of
such options or warrants or for paying taxes due as a result of the exercise of such options or warrants, the vesting of such options, warrants or Common Share awards, or as a result of the vesting of such Common Shares, it being understood that all
Common Shares received upon such exercise, vesting or transfer will remain subject to the restrictions of this agreement during the Lock-Up Period; 

(v) transfers or dispositions of shares of capital stock of the Issuer or any securities convertible into, or exercisable or exchangeable for,
such capital stock to the spouse, domestic partner, parent, child or grandchild or first cousin of the undersigned (each, an “Immediate Family Member”) or to a trust formed for the direct or indirect benefit of the undersigned or an
Immediate Family Member; 
 (vi) transfers or dispositions of shares of capital stock of the Issuer or any securities convertible into, or
exercisable or exchangeable for, such capital stock by will, other testamentary document or intestate succession to the legal representative, heir, beneficiary or trustee of the undersigned; 

(vii) transfers or dispositions of shares of capital stock of the Issuer or any securities convertible into, or exercisable or exchangeable
for, such capital stock pursuant to a divorce settlement agreement or decree or a qualified domestic relations order as defined in the United States Employee Retirement Income Security Act of 1974, as amended, or similar foreign laws; 

(viii) transfers or dispositions of shares of capital stock of the Issuer or any securities convertible into, or exercisable or exchangeable
for, such capital stock to any affiliate (as such term is defined in Rule 405 of the Securities Act of 1933, as amended), limited partners, general partners, limited liability company members or shareholders of the undersigned, or if the undersigned
is a corporation to any wholly owned subsidiary of such corporation; 
 (ix) the establishment of a trading plan pursuant to Rule 10b-5-1
under the Exchange Act for the transfer of Common Shares or securities convertible into or exchangeable for Common Shares, provided that such plan does not provide for the transfer of Common Shares during the Lock-Up Period;

  
 3 

 (x) transfers of Common Shares to the Issuer pursuant to agreements under which the Issuer has
the option to repurchase such Common Shares upon termination of the undersigned’s employment with the Issuer, provided that the repurchase price for any such Common Shares shall not exceed the original purchase price paid by the
undersigned to the Issuer for such Common Shares; and 
 (xi) transfers or other dispositions of shares of capital stock of the Issuer or any
securities convertible into, or exercisable or exchangeable for, such capital stock prior to the first public filing of the registration statement relating to the Offering; 

provided that in each case (other than (i) and (ii)), no filing by any party under Section 13 or Section 16(a) of the Exchange Act or
other public announcement shall be required or voluntarily made by the undersigned or the recipient during the Lock-Up Period; provided further that, in the case of any transfer pursuant to clause (ii), no filing by any party under
Section 16(a) of the Exchange Act shall be required or voluntarily made by the undersigned during the Lock-Up Period; provided further that, in the case of any transfer or distribution pursuant to clauses (iii), (v), (vi), (vii),
(viii) and (xi), (a) the recipient agrees to be bound in writing by the same restrictions set forth herein for the duration of the Lock-Up Period and (b) any such transfer shall not involve a disposition for value. Notwithstanding the
foregoing, the undersigned may make transfers described in clauses (iii) or (v) above prior to the date that is ten days following the initial public filing with the SEC of the registration statement relating to the Offering, provided that
(a) the recipient agrees to be bound in writing by the same restrictions set forth herein for the duration of the Lock-Up Period and (b) any such transfer shall not involve a disposition for value. 

If the undersigned is an officer or director of the Issuer, the undersigned further agrees that the foregoing restrictions shall be equally
applicable to any issuer-directed Common Shares the undersigned may purchase in the Offering. 
 If the undersigned is an officer or
director of the Issuer, (i) the Representatives agree that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of Common Shares, the Representatives will notify
the Issuer of the impending release or waiver, and (ii) the Issuer has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service at least two business days before the effective
date of the release or waiver. Any release or waiver granted by the Representatives hereunder to any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of
this paragraph will not apply if (a) the release or waiver is effected solely to permit a transfer not for consideration and (b) the transferee has agreed in writing to be bound by the same terms described in this letter to the extent and for the
duration that such terms remain in effect at the time of the transfer.

  
 4 

 The restrictions contained herein shall not apply to any transfers, sales, tenders or other
dispositions of Common Shares or any security convertible into or exercisable or exchangeable for Common Shares pursuant to a bona fide third-party tender offer, merger, amalgamation, consolidation or other similar transaction made to or involving
all holders of the Common Shares or such other securities pursuant to a change of control of the ownership of the Issuer provided that such transaction is approved by the Issuer’s Board of Directors (including, without limitation, the entry
into any lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Common Shares or other such securities in favor of any such transaction); provided that, if such
tender offer, merger, amalgamation, consolidation or other similar transaction is not completed, any Common Shares or any security convertible into or exercisable or exchangeable for Common Shares subject to this letter agreement shall remain
subject to the restrictions contained in this letter agreement. For purposes of this letter agreement, “change of control” shall mean the consummation of any bona fide third party tender offer, merger, amalgamation, consolidation or other
similar transaction the result of which is that any “person” (as defined in Section 13(d)(3) of the Exchange Act), or group of persons, other than the Issuer, becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the
Exchange Act) of 50% of the total voting power of the voting stock of the Issuer. 
 Notwithstanding anything to the contrary contained
herein, if any officer or director of the Issuer or record or beneficial owner of any securities of the Issuer other than the undersigned that beneficially owns 1% or more of the outstanding Common Shares of the Issuer (calculated on a pre-Offering
as-converted basis) (any such holder of 1% or more of the outstanding Common Shares, a “Major Holder”) is granted an early release from the restrictions described herein during the Lock-Up Period, then the undersigned
shall also be granted an early release from its obligations hereunder to the same extent and with respect to the same percentage of securities (relative to the total holdings of the stockholder being released from such restrictions) held by the
undersigned (the “Pro-rata Release”); provided, however, that no Pro-rata Release of the undersigned’s shares will occur unless the Representatives have waived such prohibitions with respect to Common Shares, or
any securities convertible into or exercisable for Common Shares, held by officers, directors and/or Major Holders valued at $5,000,000 or more in aggregate (based on the closing or last reported sale price of the Common Shares on the date such
waiver becomes effective); provided that officers and directors of the Issuer may be released from such restrictions solely due to circumstances of an emergency or hardship, as determined by the Representatives in their sole
judgment. The Pro-rata Release shall not be applied in the case of an early release from the restrictions described herein during the Lock-Up Period in connection with an underwritten public offering, whether or not such offering or sale is
wholly or partially a secondary offering of Common Shares (an “Underwritten Sale”), provided that the undersigned, to the extent the undersigned has a contractual right to demand or require the registration of the
undersigned’s Common Shares or otherwise “piggyback” on a registration statement filed by the Issuer for the offer and sale of its Common Shares, is offered the 

  
 5 

 
opportunity to participate on a basis consistent with such contractual rights in such Underwritten Sale. The Representatives shall use commercially reasonable efforts to provide notice to the
Issuer within three (3) business days upon the occurrence of a release of a shareholder of its obligations under any lock-up agreement executed in connection with the Offering that gives rise to a corresponding release of the undersigned from its
obligations hereunder pursuant to the terms of this paragraph, provided that the failure to give such notice shall not give rise to any claim or liability against the Underwriters. For purposes of determining record or beneficial
ownership of a shareholder, all Common Shares held by investment funds affiliated with such shareholder shall be aggregated. 
 This
agreement shall automatically terminate and the undersigned shall be released from all obligations under this letter upon the earliest to occur, if any, of (i) the Issuer, on the one hand, or the Representatives, on the other hand, advising the
other in writing, prior to the execution of the Underwriting Agreement, that they have determined not to proceed with the Offering, (ii) the Underwriting Agreement being terminated prior to the First Closing Date (as defined in the Underwriting
Agreement), (iii) the registration statement filed with the SEC with respect to the Offering being withdrawn and (iv) December 29, 2016, if the Offering has not been completed by such date. 

  
 6 

 
			
	Yours very truly,
	
	[insert officer, director or shareholder]
		
		 	By:
		
		 	  

		 	Name:
		
		 	  

		 	Title:
		
		 	  

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]